ISOLATED ANTIBODIES OR FRAGMENTS THAT BIND TO SOLUBLE HUMAN ST2, HYBRIDOMA, KIT, AS WELL AS METHODS

专利摘要:
antibodies and assays for soluble human st-2 The present invention relates to antibodies and antigen-binding antibody fragments that bind to st2 (growth stimulation-expressed gene 2) protein, kits containing such antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.
公开号:BR112012025728B1
申请号:R112012025728-5
申请日:2011-04-08
公开日:2022-01-11
发明作者:James V. Snider
申请人:Critical Care Diagnostics, Inc；
IPC主号:

专利说明:

CROSS REFERENCE WITH RELATED ORDERS
[0001] This application claims priority to United States provisional application 61/322,578, filed April 9, 2010 and United States provisional application 61/345,837, filed May 18, 2010, the contents of which are incorporated herein by reference in its entirety. TECHNICAL FIELD
[0002] Described herein are antibodies and antigen-binding fragments of antibodies that bind to ST2 (Growth Stimulation-Expressed Gene 2) protein, kits containing such antibodies and antibody fragments, and assays using such antibodies and antibody fragments. BACKGROUND
[0003] ST2 is a member of the interleukin-1 receptor family with transmembrane (ST2L) and soluble (sST2 or soluble ST2) isoforms (Iwahana et al., Eur. J. Biochem. 264:397-406, 1999). Recently published articles describe current knowledge about the relationship of ST2 with inflammatory diseases (Arend et al., Immunol. Rev. 223:20-38, 2008; Kakkar et al., Nat. Rev. Drug Discov. 7:827-840 , 2008; Hayakawa et al., J. Biol. Chem. 282:26369-26380, 2007; Trajkovic et al., Cytokine Growth Factor Rev. 15:87-95, 2004 ). Circulating concentrations of human soluble ST2 are elevated in patients suffering from various disorders associated with an abnormal type 2 helper T cell (Th2) response, including systemic lupus erythematosus and asthma, as well as in inflammatory conditions that are primarily independent of a response. of Th2, such as septic shock or trauma ( Trajkovic et al., Cytokine Growth Factor Rev. 15:87-95, 2004 ; Brunner et al., Intensive Care Med. 30:1468-1473, 2004 ). Additionally, interleukin-33/ST2L signaling represents a crucial cardioprotective mechanism in the event of a mechanical overload ( Seki et al., Circulation Heart Fail. 2:684691, 2009; Kakkar et al., Nat. Rev. Drug Discov. 7 :827-40, 2008; Sanada et al., J. Clin. Invest. 117:1538-1549, 2007 ). An elevation in human soluble ST2 is also predictive of a poor prognosis in patients with heart failure (HF) and those with myocardial infarction (Kakkar et al., Nat. Rev. Drug Discov. 7:827-40, 2008; Weinberg et al., Nat. Rev. Drug Discov. 7:827-40, 2008; Weinberg et al. al., Circulation 107:721-726, 2003; Shimpo et al., Circulation 109:2186-2190, 2004; Januzzi et al., J. Am. Coll. Cardiol. 50:607-613, 2007; Mueller et al. ., Clin. Chem. 54:752-756, 2008; Rehman et al., J. Am. Coll. Cardiol. 52:1458-65, 2008; Sabatine et al., Circulation 117:1936-1944, 2008 ). Elevated levels of soluble ST2 are also predictive of an individual's death within a year (see, for example, WO 07/127749). Taken together, soluble ST2 has been implicated in certain inflammatory diseases and the cardioprotective paracrine system and is a predictive marker for prognosis in patients with heart failure and death of an individual within one year. SUMMARY
[0004] The present invention is based, at least in part, on the development of new antibodies specific for human soluble ST2 protein. These antibodies and their antigen-binding fragments are useful, for example, for the quantification of soluble human ST2 proteins in biological samples (for example, clinical samples), for the prediction of risk of death within a year in an individual, to determine the discharge or initiation or continuation of therapeutic treatment (eg, inpatient treatment) of an individual and to select an individual for participation in a clinical trial. Provided herein are such antibodies and antigen-binding fragments thereof, kits containing such antibodies and antibody fragments, and various methods of using such antibodies and antibody fragments.
[0005] Provided herein are isolated antibodies and antigen-binding fragments thereof that are, or competitively bind with, an antibody produced from hybridomas deposited with the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10431 and PTA-10432. In some embodiments, the antibody or fragment thereof does not competitively bind with either one or both of the D066-3 or D067-3 antibodies (MBL International) (described in US Patent No. 7,087,396) or has a KD for binding human soluble ST2 equal to or less than 1.51 x 10 -9 M. In some embodiments, the antibody or fragment thereof has a KD for binding to human soluble ST2 equal to or less than 8.59 x 10 -10 M In some embodiments, the antibody or fragment thereof is chimeric or humanized. In some embodiments, the fragment is selected from the group of: a Fab fragment, an F(ab')2 fragment, and an scFv fragment. In some embodiments, the antibody or fragment thereof is glycosylated. In some embodiments, the antibody or fragment thereof contains one or more complementarity determining regions of the light chain or heavy chain of the antibody produced by the hybridoma deposited with the ATCC and designated by Patent Application Designations PTA-10431 and PTA-10432. In some embodiments, the antibody is an antibody produced by the hybridoma deposited with the ATCC and designated by the Patent Deposit Designation PTA-10431 or antigen-binding fragment thereof, or an antibody produced by the hybridoma deposited with the ATCC and designated by the Patent Deposit Designation PTA-10432 or its antigen-binding fragment.
[0006] Also provided are isolated antibodies and antigen-binding fragments thereof that specifically bind human soluble ST2, wherein the antibodies and antigen-binding fragments thereof were produced by a process that includes immunizing a non-human mammal (e.g. , mouse, rat, rabbit, goat, cow, pig, monkey or horse) with a recombinant human soluble ST2 isolated from a human cell (e.g., a human fibroblast, a neuronal, epithelial or endothelial cell, an embryonic or adult cell , especially a human embryonic kidney cell). In some embodiments, the isolated recombinant human soluble ST2 is fully glycosylated, i.e., has substantially the same glycosylation as a native endogenous human soluble ST2 present in human serum. In some embodiments of all antibodies and fragments described herein, the antibody or fragment thereof is labeled.
[0007] Also provided are cells from the hybridoma filed with the ATCC and designated by the Patent Filing Designation PTA-10431 and cells from the hybridoma filed with the ATCC and designated by the Filing Designation PTA-10432.
[0008] Methods for quantifying the level of human soluble ST2 in a sample from an individual are also provided. The method includes contacting the sample with at least one antibody or fragment thereof described herein and detecting binding of the antibody or fragment thereof to human soluble ST2. In some embodiments, the method includes the use of at least two different antibodies or fragments thereof described herein.
[0009] Methods of predicting risk of death within a year in an individual are also provided. Methods include obtaining a sample from a subject and determining the level of human soluble ST2 using at least one antibody or fragment thereof described herein, where an elevated level of human soluble ST2 indicates that the subject has an increased risk of death within one year. (e.g., increased risk of death within one year relative to an individual (e.g., an individual who has the same disease) who has a decreased level or a substantially equal level of soluble ST2 relative to the same control) and a Decreased or substantially equal level of human soluble ST2 indicates that the individual has a decreased risk of death within one year (e.g., decreased risk of death within one year relative to an individual (e.g., an individual who has the same disease) that has an increased level or a substantially equal level of soluble ST2 relative to the same control).
[00010] Methods are also provided for determining discharge from hospital treatment or for initiating or continuing treatment of an individual on a hospital basis including obtaining a sample from an individual and determining the level of soluble human ST2 in the sample using at least one antibody or a fragment described herein, where an elevated level of human soluble ST2 in the sample compared to the reference level of human soluble ST2 indicates that hospital treatment should be initiated or continued and a decreased or equal level of human soluble ST2 indicates that the individual should be considered for hospital discharge. In some embodiments, the individual has at least one of the following symptoms: chest pain or discomfort, shortness of breath, nausea, vomiting, belching, sweating, palpitations, delirium, fatigue, and syncope.
[00011] Methods for selecting a subject to participate in a clinical study are also provided including obtaining a sample from a subject, determining the level of human soluble ST2 in the sample using at least one antibody or fragment thereof described herein, and selecting the subject for participation in a clinical trial if the subject's human soluble ST2 level relative to a baseline human soluble ST2 level indicates that the subject should be selected to participate in the clinical trial. In some embodiments, the presence of an elevated level of human soluble ST2 indicates that the subject should be selected to participate in the clinical trial.
[00012] Also provided are methods for selecting a therapeutic treatment for a subject including determining a level of human soluble ST2 in a biological sample from the subject using at least one antibody or fragment thereof described herein, wherein the subject's human soluble ST2 level is relative to a reference level of human soluble ST2 is used to select the therapeutic treatment for the individual. In some embodiments, the presence of an elevated level of human soluble ST2 is used to select the therapeutic treatment for the individual.
[00013] In some embodiments of any of the methods described herein, the individual has not been diagnosed or is not exhibiting two or more (eg, at least three, four, or five) symptoms of a disease state; the individual has already been diagnosed as having the disease (eg, heart failure, coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure, stroke, or any of the diseases described herein); or the subject has one or more of hypertriglyceridemia, hypercholesterolemia, hypertension and body mass index > 30. In some embodiments of any of the methods described herein the determination is performed using at least two antibodies or fragments thereof described herein.
[00014] In some embodiments of any of the methods described herein, the reference level of human soluble ST2 is a threshold level of human soluble ST2. In some embodiments, the threshold level is an average level of human soluble ST2 in a healthy patient population (eg, a healthy male patient population or a healthy female population). In some embodiments of any of the methods described herein, the reference level is a level of human soluble ST2 present in a sample from an individual who does not have two or more symptoms of the disease, an individual not diagnosed as having the disease, or an individual not identified as being at risk of developing the disease.
[00015] In any of the methods described herein, the individual was not diagnosed as having a disease (e.g., heart failure, coronary artery disease, cardiovascular disease, acute coronary artery disease, acute coronary syndrome, renal failure, or stroke, or any of the diseases described here). In any of the methods described herein, the sample contains blood, serum or plasma. Any of the antibodies or fragments thereof described herein can be used in any of the methods described herein.
[00016] Also provided are methods for diagnosing a disease in an individual including obtaining a sample from an individual, determining the level of human soluble ST2 in the sample using at least one antibody or a fragment thereof described herein, and the level of at least one marker where the elevated level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 and an altered level of at least one additional marker relative to a reference level of the at least one additional marker indicates that the individual has a disease (e.g., cardiovascular disease, a lung disease, sepsis, Kawasaki disease or a Th2-associated disease or any of the diseases described herein).
[00017] Methods are also provided for determining whether an individual has a normal human soluble ST2 level (and is therefore likely to be free of a severe disease, e.g., cardiovascular disease, and a normal risk of death or hospitalization, for (e.g. within one year) including obtaining a sample from a subject and determining the level of human soluble ST2 in the sample, wherein the subject is determined to have a normal level of human soluble ST2 if the human soluble ST2 level falls by a specific range (e.g., between about 14.5 to about 25.3 ng/mL or between about 18.1 to about 19.9 ng/mL). In some embodiments, a male subject is determined to have a normal human soluble ST2 level if the human soluble ST2 level is within any range listed in Table 9. In some embodiments, a female subject is determined to have a normal human soluble ST2 level. Normal human soluble ST2 if the human soluble ST2 level is within any range listed in Table 9.
[00018] Kits are also provided containing at least one (eg, two, three, four or five) of the antibodies or fragments thereof that bind to the antigen described herein. Some embodiments of these kits contain two antibodies or fragments thereof that bind to the antigen described herein. In some embodiments of these kits, at least one of the antibodies or fragments thereof has a KD for binding to human soluble ST2 (e.g., recombinant human soluble ST2) equal to or less than 8.59 x 10 -10 M. In some embodiments. , the kit further contains a recombinant human soluble ST2 isolated from a human cell (e.g., a human embryonic kidney cell). In some embodiments, recombinant human soluble ST2 is fully glycosylated.
[00019] By the term "soluble ST2" is understood a soluble protein that contains a sequence at least 90% identical (for example, at least 95%, 96%, 97%, 98%, 99%, or 100% identical) to NCBI Accession No. NP_003847.2 (SEQ ID NO: 1) or a nucleic acid that contains a sequence at least 90% identical (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identical) to NCBI Accession No. NM_003856.2 (SEQ ID NO: 2).
[00020] By the expression "elevated" or "elevation" is meant a difference, e.g. a statistically significant difference (e.g. an increase) at a determined or measured level (e.g. a human soluble ST2 protein level) compared with a baseline level (e.g., a level of human soluble ST2 in an individual who does not have a disease, an individual who does not have two or more symptoms of a disease, or an individual not identified as being at risk of developing a disease or a threshold level of human soluble ST2). In some embodiments, the reference is a threshold level and any level above that is considered "high". Additional reference levels of human soluble ST2 are described herein.
[00021] By the term "health facility" is meant a place where an individual can receive medical care from a healthcare professional (eg, a nurse, a physician or a medical practitioner). Non-limiting examples of healthcare facilities include hospitals, clinics, and assisted care facilities (eg, home nursing).
[00022] By the term "hospital" is meant an individual who is admitted to a health care institution (eg a hospital or an assisted care institution).
[00023] By the term "hospital treatment" is meant the monitoring and/or medical treatment of an individual who is admitted to a health care institution (eg a hospital or an assisted care institution). For example, an individual receiving hospital treatment may be treated with one or more therapeutic agents by the healthcare professional or may undergo a medical procedure (e.g. surgery (e.g. organ transplant, heart bypass surgery), angioplasty , imaging (eg, MRI imaging, ultrasound imaging, and CT scan)). In other examples, one or more markers of a disease or the severity of the condition may be periodically measured by the healthcare professional to assess the severity or progression of the disease or the individual's condition.
[00024] By the expression "reference level" is meant a threshold level or a level in a control individual or a population of control patients. A reference level will depend on the test performed and can be determined by one skilled in the art. A reference level can be a baseline level or a level in the same patient measured at an early and late time point. Some non-limiting examples of reference levels of human soluble ST2 include the level of human soluble ST2 in an individual who: has not been diagnosed as having a disease; does not have at least two or more symptoms of a disease; do not have a high risk of CVD; do not have kidney failure; do not have hypertriglyceridemia, hypercholesterolemia, hypertension and/or a body mass index < 30 (eg, a BMI below 25); is not at risk of developing a disease; and/or does not suffer from a disease associated with elevated ST2 levels (e.g., cardiovascular disease, lung disease, sepsis, Kawasaki disease or a Th2 associated disease or any of the diseases described herein). Additional control patient populations are described here. Additional examples of reference levels of human soluble ST2 are threshold levels of human soluble ST2. Reference levels of human soluble ST2 can be determined using methods known in the art; some exemplary levels are described here.
[00025] In some embodiments, a ratio of two levels of human soluble ST2 in an individual is calculated. The reference ratio can be compared to a reference ratio of human soluble ST2 levels measured in a subject (e.g., any of the control subjects described herein or in the same subject), for example, a reference ratio can be a proportion of human soluble ST2 levels before and after the onset of symptoms of a disease (e.g., heart disease (e.g., heart failure, coronary artery disease, cardiovascular disease, acute coronary syndrome, and angina), renal failure, or stroke or any of the other diseases associated with increased levels of human soluble ST2 as described herein); a proportion of human soluble ST2 levels before and after diagnosis of disease (e.g. heart disease (e.g. heart failure, coronary artery disease, cardiovascular disease, acute coronary syndrome and angina), renal failure or stroke, or any other one of the other diseases described herein); a proportion of ST2 levels before and after therapeutic treatment of a disease ((heart disease (e.g. heart failure, coronary artery disease, cardiovascular disease, acute coronary syndrome and angina), renal failure or stroke, or any of the other diseases described herein); a proportion of human soluble ST2 levels at two different time points during therapeutic treatment (e.g., inpatient or outpatient treatment) for a disease (e.g., heart disease (e.g., heart failure, coronary artery disease, cardiovascular disease, acute coronary syndrome and angina), renal failure or stroke, or any of the other conditions described herein); or a proportion of human soluble ST2 levels before or after a cardiac event (e.g., a myocardial infarction).
[00026] In some embodiments, the proportion of human soluble ST2 levels measured in an individual can be compared to a threshold reference proportion. Reference proportions of human soluble ST2 can be determined using methods known in the art; Reference proportions of human soluble ST2 can be calculated using the data described herein. For example, the reference ratio of human soluble ST2 can be between about 0.7 and about 1.1 or about 1.
[00027] By the term "therapeutic treatment" or "treatment" is meant the administration of one or more pharmaceutical agents to an individual or the performance of a medical procedure on the body of an individual (e.g. surgery, such as organ transplantation or cardiac surgery). Non-limiting examples of pharmaceutical agents that can be administered to a subject include nitrates, calcium channel blockers, diuretics, thrombolytic agents, digitalis, renin-angiotensin-aldosterone system (RAAS) modulating agents (e.g., beta-adrenergic blocking agents, angiotensin converting enzyme inhibitors, aldosterone antagonists, renin inhibitors and angiotensin II receptor blockers) and cholesterol lowering agents (e.g. a statin). The term therapeutic treatment also includes an adjustment (e.g., increase or decrease) in the dose or frequency of one or more pharmaceutical agents that the subject may be taking, the administration of one or more new pharmaceutical agents to the subject, or the removal of a or more pharmaceutical agents in the subject's treatment plan.
[00028] As used herein, an "individual" is a mammal, eg a human.
[00029] As used herein, a "biological sample" includes one or more of blood, serum, plasma, urine, and body tissue. Generally, a biological sample is a sample that contains serum, blood, or plasma.
[00030] As used herein, the term "antibody" refers to a protein that generally contains heavy chain polypeptides and light chain polypeptides. Antigen recognition and binding occur within the variable regions of the heavy and light chains. Single domain antibodies, which have a heavy chain and a light chain, and antibodies with a heavy chain lacking light chains are also known. A given antibody comprises one of five different types of heavy chains, called alpha, delta, epsilon, gamma, and mu, whose categorization is based on the amino acid sequence of the heavy chain's constant region. These different types of heavy chains give rise to five classes of antibodies, IgA (including IgA1 and IgA2), IgD, IgE, IgG (IgG1, IgG2, IgG3, and IgG4) and IgM, respectively. A given antibody comprises one of two different types of light chains, called kappa or lambda, whose categorization is based on the amino acid sequence of the light chain's constant domains. IgG, IgD, and IgE antibodies generally contain two identical heavy chains and two identical light chains and two antigen-combining domains, each composed of a heavy chain variable region (VH) and a light chain variable region (VL). ). Generally, IgA antibodies are composed of two monomers, each monomer composed of two light chains and two heavy chains (as for IgG, IgD, and IgE antibodies). In this way the IgA molecule has four antigen-binding domains, again each composed of a VH and a VL. Certain IgA antibodies are monomeric as they are composed of two heavy chains and two light chains. Secreted IgM antibodies are generally composed of five monomers, each monomer composed of two heavy chains and two light chains (as for IgG and IgE antibodies). In this way, the secreted IgM molecule has ten antigen-binding domains, again each composed of a VH and a VL. The cell surface form of IgM also exists and this has a two heavy chain/two light chain structure similar to IgG, IgD and IgE antibodies.
[00031] As used herein, the term "chimeric antibody" refers to an antibody that has been engineered to comprise at least one human constant region. For example, one or all (e.g. one, two or three) of the variable regions of the light chain(s) and one or all (e.g. one, two or three) of the variable regions of the light chain(s). The heavy chain(s) of a mouse antibody (e.g., a mouse monoclonal antibody) can each be linked to a human constant region, such as without limitation a human IgG1 constant region. Chimeric antibodies are typically less immunogenic for humans relative to non-chimeric antibodies and therefore offer therapeutic benefits in certain situations. Those skilled in the art will be aware of chimeric antibodies and will also be aware of the techniques suitable for their generation. See, for example, U.S. Patent Nos. 4,816,567; 4,978,775; 4,975,369; and Pat. U.S. No. 4,816,397.
[00032] As used herein, the term "fully humanized antibodies" are antibodies or antigen-binding fragments of antibodies that contain only human-derived amino acid sequences. For example, a fully humanized antibody can be produced from a human B cell or a human hybridoma cell. In additional embodiments, the antibody may be produced from a transgenic animal that contains the locus for a human immunoglobulin heavy chain and a human immunoglobulin light chain, or contains a nucleic acid that encodes the heavy and light chains of a specific human antibody. .
[00033] "Complementarity determining region" or "CDR" as the terms are used herein, refer to short sequences of polypeptides within the variable region of both heavy and light polypeptide chains that are primarily responsible for mediating the recognition of the specific antigen. CDRs have been described by Kabat, et al., J. Biol. Chem. 252, 6609-6616, 1977; Chothia et al., J. Mol. Biol. 196:901-917, 1987; and MacCallum et al., J. Mol. Biol. 262:732-745, 1996. There are three CDRs (termed CDR1, CDR2, and CDR3) within each VL and each VH.
[00034] "Fragment" or "antibody fragment" as the terms are used herein, refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy chain and/or light chain polypeptide ) that does not comprise a full-length antibody polypeptide, but still comprises at least a portion of a full-length antibody polypeptide that is capable of binding an antigen. Antibody fragments can comprise a cleaved portion of a full-length antibody polypeptide, although expression is not limited to such cleaved fragments. Antibody fragments can include, for example, Fab fragments, F(ab')2 fragments, scFv fragments (single chain Fv), linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific and multispecific antibodies (e.g. diabodies, triabodies, tetrabodies), minibodies, recombinant chelating antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), immunoglobulin-binding domain fusion proteins, camelized antibodies, and antibodies containing VHH. Examples of antibody fragments that bind antigen are known in the art.
[00035] "Framework region" as the expression is used herein, refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining positioning of the CDR sequences to allow binding to the antigen. Although the framework regions themselves typically do not participate directly in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies may directly participate in antigen binding or may affect the ability of one or more amino acids in the CDRs to interact. with the antigen.
[00036] "Humanized antibody" as the term is used herein, refers to an antibody that has been engineered to comprise one or more human framework regions in the variable region along with non-human complementarity determining regions (CDRs) (e.g., mouse, rat or hamster) of the heavy and/or light chain. In some embodiments, a humanized antibody comprises sequences that are entirely human, except for the CDR regions. Humanized antibodies are typically less immunogenic for humans than non-humanized antibodies, and therefore offer therapeutic benefits in certain situations. Humanized antibodies are known in the art and techniques suitable for generating humanized antibodies are also known. See, for example, Hwang et al., Methods 36:35, 2005; Queen et al., Proc. natl. academy Sci. U.S.A. 86:10029-10033, 1989; Jones et al., Nature 321:522-25, 1986; Riechmann et al., Nature 332:323-27, 1988; Verhoeyen et al., Science 239:1534-36, 1988; Orlandi et al., Proc. natl. academy Sci. U.S.A. 86:3833-3837, 1989; U.S. Patent Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370; and WO 90/07861.
[00037] As used herein, the term "Th2-associated disease" refers to a disease associated with an abnormal type 2 (Th2) T helper cell response.
[00038] As used herein, the term "cardiovascular disease" refers to a disorder of the heart and blood vessels and includes disorders of the arteries, veins, arterioles, venules and capillaries.
[00039] As used herein, the term "lung disease" refers to a disorder of the lungs.
[00040] By the term "additional marker" is understood a protein, nucleic acid, lipid or carbohydrate or a combination thereof (e.g. two or more) which is diagnostic of the presence of a particular disease. Methods described herein for diagnosing a subject as having a disease may include detecting a level of human soluble ST2 and at least one additional marker in a sample from a subject. Several additional markers useful for diagnosing a disease are known in the art (e.g., proANP, NT-proANP, ANP, proBNP, NT-proBNP, BNP, troponin, CRP, creatinine, Blood Urea Nitrogen (BUN), enzymes of liver, albumin and bacterial endotoxin; and those markers described in US Patent Application Nos.: 2007/0248981; 2011/0053170; 2010/0009356; 2010/0055683; 2009/0264779; each of which is incorporated herein by reference).
[00041] By the term "hypertriglyceridemia" is understood herein a triglyceride level that is greater than or equal to 180 ng/mL (eg greater than or equal to 200 ng/mL).
[00042] By the term "hypercholesterolemia" is understood herein an increased level of at least one form of cholesterol or total cholesterol in an individual. For example, an individual with hypercholesterolemia may have a high-density lipoprotein (HDL) level > 40 mg/dL (eg, > 50 mg/dL or > 60 mg/mL), a low-density lipoprotein (LDL) level ) of > 130 mg/dL (eg, > 160 mg/dL or > 200 mg/dL), and/or a total cholesterol level of > 200 mg/dL (eg, 240 mg/dL).
[00043] By the term "hypertension" is meant an increased level of systolic and/or diastolic blood pressure. For example, an individual with hypertension may have a systolic blood pressure that is ≥ 120 mmHg (eg, ≥ 140 mmHg or ≥ 160 mmHg) and/or a diastolic blood pressure that is ≥ 80 mmHg (eg, ≥ 90 mmHg or ≥ 100 mmHg).
[00044] By the term "healthy individual" is meant an individual who does not have a disease (eg cardiovascular disease or lung disease). For example, a healthy individual has not been diagnosed as having a disease and is not exhibiting one or more (eg, two, three, four, or five) symptoms of a disease state.
[00045] By "risk of death" is meant the risk of death of an individual from a disease or complications associated with a disease compared to a reference population (eg, a healthy control population). The term risk of death as used herein excludes intentional or accidental death, for example, blunt or crushing trauma, such as a car accident.
[00046] Unless defined otherwise, all technical and scientific expressions used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Methods and materials are described herein for use in the present invention. Other suitable methods and materials known in the art may also be used. The materials, methods and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries and references mentioned herein are incorporated by reference in their entirety. In the event of conflict, this order, including definitions, will control;
[00047] Other aspects and advantages of the invention will become apparent from the detailed description and figures below and from the claims. DESCRIPTION OF THE FIGURES
[00048] Figure 1 is an image showing the results of SDS-PAGE gel analysis of fractions from the purification of recombinant human soluble ST2 protein. The bands (10 μL of sample per band) are as follows: 1 - MWM (5 μL); 2 - His ladder (3 μL); 3 - non-transfected negative control; 4 - supernatant before purification; 5 - flow through the column; 6 - wash 1 with binding buffer; 7 - 5 mM wash 2; 8 - 5 mM wash 3; 9 - 200 mM eluted fraction 2; 10 - 200 mM eluted fraction 3; 11 - 200 mM eluted fraction 4; 12 - 200 mM eluted fraction 5; 13 - 200 mM eluted fraction 6; 14 - 200 mM eluted fraction 7; and 15 - 0.3 μg of soluble ST2.
[00049] Figure 2 shows a Western blot of purification fractions that detect the histidine tag in recombinant human soluble ST2 protein. The bands (10 μL of sample per band) are as follows: 1 - MWM (5 μL); 2 - His ladder (3 μL); 3 - supernatant before purification; 4 - flow through the column; 5 - wash 1 with binding buffer 1; 6 - wash 2 with binding buffer 2; 7 - 5 mM wash 2; 8 - 5 mM wash 3; 9 - 200 mM eluted fraction 2; 10 - 200 mM eluted fraction 3; 11 - 200 mM eluted fraction 4; 12 - 200 mM eluted fraction 5; 13 - 200 mM eluted fraction 6; 14 - 200 mM eluted fraction 7; and 15 - 0.3 μg of soluble ST2.
[00050] Figure 3 shows a Coomassie gel (Figure 3A) and two Western blots of purified recombinant soluble ST2 comparing the commercial anti-ST2 antibody D066 (MBL International) (Figure 3B) with the antibody to hexahistidine (Figure 3C). ). The bands (10 μL of sample per band) are as follows: 1 - MWM (5 μL); 2 - His ladder; 3 - 1000 ng ST2-His serum; 4 - 500 ng ST2-His serum; 5 - 200 ng ST2-His serum; 6 - 100 ng ST2-His serum; 7 - 50 ng ST2-His serum; 8 - ST2-His without Serum 1000 ng; 9 - ST2-His without Serum 500 ng; 10 - ST2-His without Serum 200 ng; 11 - ST2-His without Serum 100 ng; and 12 - ST2-His without Serum 50 ng.
[00051] Figure 4 is a linear graph showing the results of an antigen sensitivity assessment of the 7E4 and 9F8 antibodies.
[00052] Figure 5 is a linear graph showing the results of an antigen sensitivity assessment of the 7E4 and 9F8 antibodies. Antibodies 7E4 and 9F8 were coated onto individual wells of a 96-well plate at a concentration ranging from 5 µg/mL to 0 and tested against a single concentration of biotin-conjugated recombinant soluble ST2.
[00053] Figure 6 is a linear graph showing the test results in terms of their ability to be used together in a monoclonal antibody sandwich enzyme immunoassay (EIA) setup, in which either the 7E4 or 9F8 antibody is biotinylated.
[00054] Figures 7A-7F are six graphs showing the results of surface plasma resonance (SPR) analysis of antibody-antigen complex formation. Figure 7A shows SPR analysis of the 9F8 (L1) antibody. Figure 7B shows SPR analysis of the 7E4 (L2) antibody. Figure 7C shows SPR analysis of antibody 11A7 (L3). Figure 7D shows SPR analysis of antibody D066 (L4). Figure 7E shows SPR analysis of antibody D067 (L5). Figure 7F shows SPR analysis of an irrelevant antibody (L6).
[00055] Figures 8A-8F are six graphs showing the results of the SPR analysis of antibody-antigen complex formation. Figure 8A shows SPR analysis of the 9F8 (L1) antibody. Figure 8B shows SPR analysis of the 7E4 antibody (L2). Figure 8C shows SPR analysis of antibody 11A7 (L3). Figure 8D shows SPR analysis of antibody 15D6 (L4). Figure 8E shows SPR analysis of antibody D066 (L5). Figure 8F shows SPR analysis of antibody D067 (L6).
[00056] Figure 9 is a Box-whisker plot showing human soluble ST2 concentrations by anticoagulant tube type.
[00057] Figure 10 is a histogram showing the distribution of human soluble ST2 concentration in normal healthy donors.
[00058] Figure 11 is a Box-whisker plot showing human soluble ST2 concentrations as a function of sex and age in normal healthy donors. DETAILED DESCRIPTION
[00059] Described herein are antibodies and antigen-binding fragments thereof that specifically bind human soluble ST2, kits containing such antibodies and fragments, and methods of using such antibodies and fragments. ST2
[00060] The ST2 gene is a member of the interleukin-1 receptor family whose protein product exists as a transmembrane form as well as a soluble receptor that is detectable in serum (Kieser et al., FEBS Lett. 372(2-) 3):189-193, 1995; Kumar et al., J. Biol. Chem. 270(46):27905-27913, 1995; Yanagisawa et al., FEBS Lett. 302(1):51-53, 1992; Kuroiwa et al., Hybridoma 19(2):151-159, 2000 ). Soluble ST2 has been reported to be markedly up-regulated in an experimental model of heart failure (Weinberg et al., Circulation 106(23):2961-2966, 2002), and the data suggest that human soluble ST2 concentrations are also elevated in those with severe chronic heart failure (Weinberg et al., Circulation 107(5):721-726, 2003), as well as in those with acute myocardial infarction (Shimpo et al., Circulation 109(18):2186-2190, 2004).
[00061] Without wishing to be bound by theory, the transmembrane form of ST2 is considered to play a role in type 2 helper T cell modulatory responses (Lohning et al., Proc. Natl. Acad. Sci. USA 95(12): 6930-6935, 1998; Schmitz et al., Immunity 23(5):479-490, 2005), and may play a role in the development of tolerance in states of severe or chronic inflammation (Brint et al., Nat. Immunol. 5(4):373-379, 2004), while the soluble form of ST2 is upregulated in growth-stimulated fibroblasts (Yanagisawa et al., 1992, supra). Experimental data suggest that the ST2 gene is markedly upregulated in cardiomyocyte stretch states (Weinberg et al., 2002, supra) in a manner analogous to induction of the BNP gene (Bruneau et al., Cardiovasc. Res. 28(10) ):1519-1525, 1994).
[00062] Tominaga et al. (FEBS Lett. 258:301-304, 1989) isolated murine genes that were expressed specifically by stimulating growth in BALB/c-3T3 cells. Haga et al. (Eur. J. Biochem. 270:163-170, 2003 ) described that the ST2 gene was named on the basis of its induction by growth stimulation. The ST2 gene encodes two protein products: ST2 or sST2 which is a soluble secreted form and ST2L, a transmembrane receptor form that is very similar to interleukin-1 receptors. The HUGO Nomenclature Committee designated the human homolog of ST2, whose cloning was described in Tominaga et al., Biochim. Biophys. Minutes 1171:215-218, 1992 , as Interleukin 1-Like Receptor 1 (IL1R1). The two expressions are used interchangeably here.
[00063] The mRNA sequence of the shorter soluble isoform of human ST2 can be found in GenBank Accession No. NM_003856.2 (SEQ ID NO: 2), and the polypeptide sequence is in GenBank Accession No. NP_003847 .2 (SEQ ID NO: 1). The mRNA sequence of the longer form of human ST2 is in GenBank Accession No. NM_016232.4 (SEQ ID NO: 4), and the polypeptide sequence is in GenBank Accession No. NP_057316.3 (SEQ ID NO: : 3). Additional information is available in the public databases at GeneID: 9173, MIM ID # 601203, and UniGene No. Hs.66. In general, in the methods described herein, the polypeptide of the human soluble form of ST2 is measured. Antibodies and Antibody Fragments that Bind to Antigen
[00064] Provided herein are isolated antibodies and antigen-binding fragments thereof that bind human soluble ST2. The provided antibodies and fragments thereof can competitively bind with an antibody produced by the hybridoma deposited with the ATCC and designated by Patent Deposit Designation PTA-10431 or PTA-10432 (corresponding to antibodies 7E4 and 9F8, respectively). In some embodiments, the antibody or fragment does not competitively bind with antibody D066-3 and D067-3 (MBL International) (described in US Patent No. 7,087,396) and has a KD for binding to human soluble ST2 equal to or less than 1.51 x 10 -9 M. In some embodiments, the antibody or fragment has a K D for binding to human soluble ST2 equal to or less than 8.59 x 10 -10 M. Methods for determining affinity (KD) of an antibody or fragment by binding to human soluble ST2 are described herein (e.g., surface plasma resonance) and additional methods are known in the art. Also provided are monoclonal antibodies 7E4 and 9F8, produced by the methods described herein, and antigen-binding fragments thereof.
[00065] As used herein, the phrase "binds competitively" refers to the situation whereby binding of an antibody or antibody fragment to a given antigen decreases the binding of a second antibody or antibody fragment to that same antigen. In some embodiments, an antibody or fragment binds competitively with another antibody or fragment when the two antibodies or fragments bind substantially to the same epitope present on a given antigen (e.g., human soluble ST2). As shown in more detail in the Examples below, each of the antibodies produced by the hybridomas designated by the Patent Application Designations PTA-10431 and PTA-10432 recognize an epitope that is different from several other antibodies that have been tested (e.g., antibodies D066-3 and D067-3 from MBL International) and therefore do not bind competitively with those test antibodies. In some embodiments, an antibody or fragment described herein binds an epitope on human soluble ST2 that is recognized by an antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432. Methods for determining whether two different antibodies or fragments bind competitively are described herein and are known in the art (e.g., competitive enzyme-linked immunosorbent assays).
[00066] In some embodiments, the antibodies or fragments bind or show enhanced binding to an epitope present on recombinant human soluble ST2 protein that is produced by a human cell (e.g., a human fibroblast, an epithelial, endothelial, or neuronal cell, an embryonic or adult cell or a human embryonic kidney cell, e.g. HEK293) that is not present in a recombinant human soluble ST2 that is produced in a non-human cell type. In some embodiments, the antibodies or fragments bind or show enhanced binding to an epitope present on a fully glycosylated human soluble ST2 protein (e.g., a human soluble ST2 protein isolated from human cells) that is not present on a recombinant human soluble ST2 protein. that is non-glycosylated or incorrectly or sub-glycosylated (e.g. not completely glycosylated or is glycosylated in a pattern (e.g. number, position and/or type of sugars that are not present in native human soluble ST2 present in a human, for example, in human serum.) In some embodiments, the antibodies and antibody fragments bind native human soluble ST2 better (eg, with increased affinity) than other commercially available antibodies.
[00067] In some embodiments, the antibody is either a monoclonal antibody produced by the hybridoma deposited with the ATCC and designated by Patent Deposit Designation PTA-10431 (the 7E4 antibody) or is an antigen-binding fragment of the antibody produced by the deposited hybridoma in the ATCC and designated by Patent Application Designation PTA-10431 (7E4 antibody fragments). In some embodiments, the antibody is either a monoclonal antibody produced by the hybridoma deposited with the ATCC and designated Patent Deposit Designation PTA-10432 (the 9F8 antibody) or is an antigen-binding fragment of the antibody produced by the hybridoma deposited with the ATCC and designated by Patent Application Designation PTA-10432 (9F8 antibody fragments). Combinations of two or more of the antibodies or fragments described herein (e.g., two or more than one 7E4 antibody, 7E4 antibody fragments, 9F8 antibody, and 9F8 antibody fragments) are useful in any of the methods described herein.
[00068] Monoclonal antibodies that bind human soluble ST2 produced by hybridomas designated by Patent Application Designation PTA-10431 and Patent Application Designation PTA-10432 were each generated by immunizing a non-human mammal with Recombinant human soluble ST2 isolated from human kidney embryonic cells (HEK-293). Human soluble ST2 has a significant amount/number of post-translational modifications. Based on its amino acid sequence, human soluble ST2 has a predicted molecular weight of about 36 kDa. However, the native protein has a molecular weight of about 58 kDa, due to the presence of post-translational modifications. As is known in the art, such post-translational modifications can have an effect on the ability of an antibody or antibody fragment to bind a given protein. Therefore, as described in more detail in the Examples section below, monoclonal antibodies that bind human soluble ST2 produced by hybridomas designated by Patent Application Designation PTA-10431 have a higher affinity for native human soluble ST2 than other antibodies and , therefore, is useful as diagnostics and other reagents.
[00069] In some embodiments, an antibody or fragment described herein comprises the heavy and/or light chain (or a fragment thereof) of the antibody produced by the hybridomas designated by Patent Application Designation PTA-10431 and/or PTA-10432. In some embodiments, an antibody or fragment described herein comprises the heavy and/or light chain (or a fragment thereof) of the antibody produced by the hybridomas designated by Patent Application Designation PTA-10431 and/or PTA-10432.
[00070] As is known in the art, the specificity of an antibody against a given antigen is mediated by the heavy and light chain variable regions. In particular, the specificity of an antibody against a given antigen is primarily determined by the short sequences within the heavy and light chain variable regions called complementarity determining regions or CDRs. In some embodiments, an antibody or fragment described herein contains one or more (e.g., one, two, three, four, five or six) CDRs of the light and/or heavy chain of the antibody produced by the hybridoma designated by the Patent Application Designation PTA-10431 and/or PTA-10432. In some embodiments, an antibody or fragment described herein comprises each of the heavy chain CDRs of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432. In some embodiments, an antibody or fragment described herein comprises each of the light chain CDRs of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432. In some embodiments, an antibody or fragment described herein comprises each of the antibody CDRs (all heavy and light chain CDRs) produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432.
[00071] Also provided are isolated antibodies and antigen-binding antibody fragments that specifically bind human soluble ST2 that are produced by a process that includes immunizing a non-human mammal with a recombinant human soluble ST2 isolated from a kidney cell ( e.g. a human kidney cell, an embryonic kidney cell and a human embryonic kidney cell). In some embodiments, the human recombinant soluble ST2 is completely glycosylated or contains all of the post-translational modifications present in the native soluble ST2 protein.
[00072] In some embodiments, an antibody or fragment described herein is chimeric, characterized in that it comprises at least one human constant region. For example, constant regions of antibodies produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432 can be replaced with a human constant region. Chimeric antibodies are typically less immunogenic for humans, relative to non-chimeric antibodies, and therefore offer therapeutic benefits in certain situations. In some embodiments, a chimeric antibody described herein comprises an IgG1 constant region. Those skilled in the art will be aware of a variety of human constant regions. Methods for making chimeric antibodies are known in the art.
[00073] In some embodiments, an antibody or fragment described herein is humanized, characterized in that it comprises at least one human framework region. For example, one or more (one, two, three, four, five or six) framework regions of antibodies produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432 may be replaced by one or more human framework regions. . Humanized antibodies are typically less immunogenic for humans, relative to non-humanized antibodies, and therefore offer therapeutic benefits in certain situations. Those skilled in the art will be aware of a variety of human framework regions. Methods for making humanized antibodies are known in the art.
[00074] For example, methods based on CDR homology can be used for humanization (see, for example, Hwang et al., Methods 36:35, 2005). These methods generally involve substituting non-human CDRs into a human variable domain structure based on the similarity of non-human and human structured CDRs, rather than the similarity of human and non-human structured structures. The similarity of non-human and human CDRs is generally determined by identifying human genes of the same type of chain (light or heavy) that have the same combination of canonical CDR structures as the non-human (e.g., mouse) binding molecules. and therefore retains the three-dimensional conformation of the CDR peptide scaffolds. Second, for each of the candidate variable genes with matching canonical structures, the residue-to-residue homology between the candidate non-human and human CDRs is evaluated. Finally, to generate a humanized binding molecule, the CDR residues of the chosen human candidate CDR not yet identical with the non-human CDR, are converted to the non-human (e.g., mouse) sequence. In some embodiments, no human framework mutation is introduced into the humanized binding molecule.
[00075] In some embodiments, the replacement of non-human CDRs in a human variable domain structure is based on retaining the correct spatial orientation of the non-human variable domain structure by identifying the human variable domain structures that will retain the same conformation as the non-human variable domain structures from which the CDRs were derived. In some embodiments, this is achieved by obtaining the human variable domains of human binding molecules whose framework sequences exhibit a high degree of sequence identity to the non-human variable framework domains from which the CDRs were derived. See, for example, Kettleborough et al., Protein Engineering 4:773, 1991; Kolbinger et al., Protein Engineering 6:971, 1993; and WO 92/22653.
[00076] In some embodiments, an antibody or fragment described herein is monospecific characterized in that it recognizes only a single epitope. Monospecific antibodies are known in the art (see, for example, WO 9639858). In some embodiments, an antibody or fragment described herein is bispecific, characterized in that it recognizes more than one epitope (eg, two epitopes). Bispecific antibodies are known in the art (see, for example, U.S. Patent Application Publication No. 2009/0162360 ). In some embodiments, monospecific or bispecific antibodies or fragments described herein bind to the epitope recognized by an antibody or antibody fragment that has the CDRs of the monoclonal antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432. In some embodiments, a bispecific antibody or fragment binds to human soluble ST2 as well as a different non-ST2 polypeptide. In some embodiments, a bispecific antibody or fragment binds to two different epitopes of human soluble ST2. In some embodiments, an antibody or fragment described herein is divalent (see, for example, WO 1999/064460). For a further description of other types of antibodies and fragments that may include one or more of the CDRs of the monoclonal antibodies produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432, see US Patent Application Publication No. 20070105199 and WO 2007/059782.
[00077] In some embodiments, a fragment (eg, an antigen-binding fragment) is derived from a complete antibody molecule, for example, a monoclonal antibody. The antibody can, for example, be cleaved on the carboxy terminal side of its hinge region (e.g. with pepsin) to generate an F(ab')2 fragment or on the amino terminal side of its hinge region (e.g. , with papain) to generate Fab fragments. In some embodiments, the antigen-binding fragment described herein is a Fab fragment, F(ab')2 fragment, scFv fragment (single-chain Fv), linear antibodies, antibody fragments monospecific or multispecific such as bispecific, trispecific and multispecific antibodies (e.g. diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding domain fusion proteins of immunoglobulin, camelized antibodies and antibodies that contain HVH. Methods for producing such fragments are known in the art.
[00078] In some embodiments, an antibody that binds to human soluble ST2 or an antibody fragment that binds to the antigen described herein contains a polypeptide that has one or more amino acid substitutions, deletions, or insertions as compared to the heavy chain and /or light of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432. Substitutions, deletions or insertions can be introduced by standard techniques, such as site-directed mutagenesis or PCR-mediated mutagenesis, of a nucleic acid molecule encoding a polypeptide comprising the heavy and/or light chain of the antibody produced by the designated hybridoma. by Patent Application Designation PTA-10431 or PTA-10432 (e.g., a nucleic acid encoding one or more (e.g., one, two, or three) of the heavy or light chain CDR regions. In some embodiments, substitutions Conservative amino acid substitutions are made at one or more positions. A "conservative amino acid substitution" is one in which the amino acid residue is replaced by an amino acid residue that has a similar side chain. Families of amino acid residues that have similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g. tyrosine, phenylalanine, tryptophan, histidine). Therefore, an amino acid residue in a soluble human anti-ST2 antibody polypeptide or an antibody fragment that binds human soluble ST2 can be substituted for another amino acid residue of the same side chain family.
[00079] In some embodiments, an antibody that binds human soluble ST2 or an antibody fragment that binds human soluble ST2 described herein comprises an amino acid sequence that is at least 90% identical, at least 95%, 96% , 97%, 98%, 99%, or 100% identical to the heavy or light chain of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432 (e.g., at least 90%, 95%, 96 %, 97%, 98%, 99% or 100% identical to at least one (e.g., one, two or three) CDRs of the heavy or light chain of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432). For example, an antibody that binds human soluble ST2 or an antibody fragment that binds human soluble ST2 described herein may contain one or more CDRs that contain one or more amino acid substitutions, deletions, or insertions in the corresponding CDR sequence found in the heavy or light chain of the antibody produced by the hybridoma designated by Patent Application Designation PTA-10431 or PTA-10432.
[00080] In some embodiments, the compositions described herein contain two or more antibodies that bind human soluble ST2 or fragments of antibodies that bind human soluble ST2 described herein. For example, a composition described herein may contain antibodies produced by each of the hybridomas designated by Patent Application Designation PTA-10431 or PTA-10432. As described in more detail in the Examples section below, such a combination of antibodies exhibits increased affinity for the ST2 antigen when compared to any individual antibody and when compared to other commercially available antigen-binding antibodies. Such compositions containing the antibodies or antigen-binding fragments described herein will be useful in a variety of methods, for example, diagnostic methods. In some embodiments, the compositions described herein contain two and one more antigen-binding fragments (e.g., Fab fragments, F(ab)2 fragments, or scFv fragments), such as fragments derived from antibodies produced by each of the hybridomas designated by the Patent Application Designation PTA-10431 or PTA-10432.
[00081] In any of the above methods, antibodies or antibody fragments can be labeled with a detectable substance including, but not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, fluorescein dichlorotriazinylamine, dansyl chloride, quantum dots or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin and aequorin and examples of suitable radioactive materials include 125I, 131I, 35S, or 3H. hybridomas
[00082] Also provided herein are novel hybridomas that produce antibodies that bind human soluble ST2. As is known in the art, the term "hybridoma" refers to a cell that is produced by the fusion of an antibody-producing lymphocyte and a non-antibody-producing cancer cell, usually a myeloma or lymphoma. After fusion, hybridomas proliferate and produce the specific monoclonal antibody that was originally produced by the fused lymphocyte. In some embodiments, the hybridoma provided is a hybridoma deposited with the ATCC and designated by Patent Filing Designation PTA-10431 or PTA-10432. In some embodiments, individual cells, harvested cells, and cultures containing cells that are derived from the hybridoma filed with the ATCC and designated by Patent Filing Designation PTA-10431 or PTA-10432 are also provided. Methods of Use of the Antibodies and Fragments Provided
[00083] One or more of any of the antibodies or antibody fragments described herein may be used in methods for quantifying the level of human soluble ST2 in a sample, e.g., a sample from an individual, especially to predict risk of death within one year, determine the discharge or initiation or continuation of an individual's treatment on a hospital basis, select an individual to participate in a clinical trial, diagnose an individual as having a disease, or identify an individual at risk of developing a disease. Human Soluble ST2 Level Quantification Methods
[00084] Methods for determining the level of human soluble ST2 in a sample from a subject are provided including contacting the sample with at least one antibody or antibody fragment described herein; and detecting binding of the antibody or fragment to human soluble ST2. In some embodiments, at least two (e.g., two, three, or four) antibodies or antibody fragments described herein are used to determine the level of human soluble ST2 in a sample from a subject. In some embodiments, the individual is undiagnosed or is not exhibiting one or more (eg, two, three, or four) symptoms of a disease. In some embodiments, the individual has already been diagnosed as having a disease associated with elevated levels of ST2 (e.g., heart failure, coronary artery disease, cardiovascular disease, acute coronary syndrome, renal failure, stroke, or any other disease described herein. ). In some embodiments, the individual has one or more (eg, two, three, or four) of: hypertriglyceridemia, hypercholesterolemia, hypertension, renal failure, and a body mass index > 30. In some embodiments, the sample contains blood, serum, or plasma .
[00085] In some embodiments, the sample may be collected from the individual by a healthcare professional (eg, a phlebotomist, a physician, a nurse, an attending physician, or a laboratory technician). The sample can be stored (e.g., at < 4 °C, < 0 °C, or -80 °C) for a period of time before the sample is contacted with at least one antibody or fragment described herein and the binding of the antibody or fragment is detected. Methods for contacting a biological sample with an antibody or antibody fragment and detecting binding of the antibody or fragment are described herein and additional methods are known in the art. Quantitation may include control experiments to detect binding of at least one antibody or antibody fragment described herein to a purified recombinant human soluble ST2 (e.g., a recombinant human soluble ST2 isolated from human kidney embryonic cells).
[00086] In some embodiments, the level of human soluble ST2 in a normal or healthy individual is quantified. A normal or healthy individual is an individual who does not suffer from an ST2-associated condition (e.g., an ST2-associated condition described herein), is not diagnosed as having a disease (e.g., any of the diseases described herein), and is not has two or more (eg, two, three, or four) symptoms of a disease. Normal or healthy individuals can be confirmed by any of a variety of known techniques, including without limitation, by biomarker screening or physical examination (e.g., by the outward manifestation of the absence of two or more symptoms associated with a condition associated with ST2 or any other disease described here). For example, normal or healthy individuals can be screened for the absence of occult CVD or inflammatory disease by screening for low levels of one or more markers including, but not limited to, brain natriuretic peptide (BNP), procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6). Those skilled in the art will be aware of other markers suitable for determining that a normal or healthy individual does not exhibit occult CVD or inflammatory disease or any other disease described herein.
[00087] The quantification of human soluble ST2 levels in a sample from an individual (eg, a normal or healthy individual) is useful in a variety of circumstances. In some embodiments, human soluble ST2 levels of individuals (e.g., normal or healthy individuals, individuals who are at increased risk of developing a disease, individuals diagnosed with a disease, or individuals who have two or more symptoms of a disease) may be quantified at periodic intervals, e.g. daily, weekly, biweekly, monthly, bimonthly, annually, etc. or periodic physical examination. Any of a variety of techniques known to those skilled in the art, including those described herein, can be used to quantitate human soluble ST2 levels in an individual using the antibodies and antigen-binding fragments of antibodies described herein.
[00088] In some embodiments, the level of human soluble ST2 in a control individual (e.g., a normal or healthy individual) is quantified to arrive at a reference level for use in determining that an individual does not have a condition. associated with ST2, is at risk of developing a disease or is at risk of dying within one year. For example, human soluble ST2 levels in an individual not suffering from a disease such as, without limitation, cardiovascular disease, heart failure, coronary artery disease, acute coronary syndrome, renal failure, stroke, lung disease, sepsis , Kawasaki disease or a Th2 associated disease or any other disease described herein can be quantified to arrive at a baseline level of human soluble ST2.
[00089] In some embodiments, at least one of any of the antibodies or antigen-binding fragments described herein can be used to quantitate human soluble ST2 levels in a subject (eg, a normal or healthy subject). For example, human soluble ST2 levels in a subject (e.g., a normal or healthy subject) can be quantified by immunoassays using at least one of any of the antibodies or antigen-binding fragments described herein (e.g., a antibody or fragment that competitively binds with an antibody produced by a hybridoma deposited with the ATCC and designated by Patent Deposit Designation PTA-10431 or PTA-10432 or both).
[00090] In some embodiments, the level of human soluble ST2 in a sample is quantified to ensure reproducibility of routine performance, reference ranges, clinical cutoffs and the like. For example, human soluble ST2 levels in two or more samples, e.g. reference samples, can be quantified and the coefficient of variation ("CV") between the human soluble ST2 levels of two or more samples can be evaluated. . Additionally or alternatively, the level of human soluble ST2 in the sample (or subject) can be quantified over two or more separate time periods (e.g. using different batches of a reference sample or different samples taken from the same subject) and the Cv between human soluble ST2 levels can be determined. In some modalities, the CV between human soluble ST2 levels is less than 20%, e.g. less than 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12% 11% , 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less.
[00091] In some embodiments, methods are provided for determining whether an individual has a normal level of human soluble ST2. Determining whether an individual has a normal level of human soluble ST2 is useful in a variety of circumstances. In some embodiments, methods of determining whether a subject has a normal level of human soluble ST2 comprise assaying the level of human soluble ST2 in a sample from the subject (e.g., any of the samples described above such as, without limitation, samples containing blood, serum or plasma), in which the subject is determined to have a normal level of human soluble ST2, if the level of human soluble ST2 in the sample is found to be substantially similar to the known or median normal level of human soluble ST2 or if the level of human soluble ST2 in the sample falls within a certain range, e.g. around a known normal or median level of human soluble ST2 (e.g. the 95% confidence interval or the interquartile range or any of the ranges listed in Table 9). For example, a subject can be determined to have a normal human soluble ST2 level if a sample from the subject is assayed and the human soluble ST2 level in the sample is found to be within the 95% confidence interval around a known normal level. or median human soluble ST2, for example, an average level in a normal or healthy individual. Additionally or alternatively, a subject can be determined to have a normal level of human soluble ST2 if a sample from the subject is assayed and the level of human soluble ST2 in the sample is found to be in the interquartile range around a known normal or median ST2 level. human soluble.
[00092] In some embodiments, a subject is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the subject's sample is about 18.8 ng/mL. In some embodiments, an individual is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the sample is within the range of about 14.5 to about 25.3 ng/mL. In some embodiments, an individual is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the sample is within the range of about 18.1 to about 19.9 ng/mL.
[00093] In some embodiments, a female subject is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the subject's sample is about 16.2 ng/mL. In some embodiments, a female is determined to have a normal human soluble ST2 level if the human soluble ST2 level in the sample is within any of the ranges listed in Table 9.
[00094] In some embodiments, a male subject is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the subject's sample is about 23.6 ng/mL. In some embodiments, a male is determined to have a normal human soluble ST2 level if the human soluble ST2 level in the sample is within any of the ranges listed in Table 9.
[00095] In some embodiments, a subject (e.g., male or female subject) is determined to have a normal level of human soluble ST2 if the level of human soluble ST2 in the subject's sample is below a threshold (e.g., 25.3 ng/mL or 19.9 ng/mL (for females) or 30.6 ng/mL (for males)).
[00096] The expression "about" or "substantially the same" as used in reference to a value or range of human soluble ST2 levels (e.g., a range of normal human soluble ST2 levels) in an individual refers to to an interval around the reference value or range, e.g. a value or range which one skilled in the art considers equivalent to the reference value or range (e.g. any of the ranges listed in Table 9) for the purpose of evaluating human soluble ST2 levels (eg, normal human soluble ST2 levels or human soluble ST2 levels in a group of patients who have a disease or who have two or more symptoms of disease). As used here, a value or range of human soluble ST2 levels (e.g. normal human soluble ST2 levels) is "around" a reference value or range when it is within +/- 25% of the value or range of reference, for example, +/-20%, +/-15%, +/-10%, +/-9%, +/-8%, +/7%, +/-6%, +/-5 %, +/-4%, +/-3%, +/-2%, or +/-1% of the value or range.
[00097] In some embodiments, at least one or two of any of the antibodies or antigen-binding fragments described herein can be used to determine whether an individual has a normal level of human soluble ST2, a level of human soluble ST2 that is correlated with a disease or a level of human soluble ST2 that is correlated with an increased risk of developing a disease or an increased risk of dying within one year. Methods of Predicting Risk of Mortality Within One Year
[00098] Also provided are methods of predicting risk of mortality in a subject within a year which include obtaining a sample from a subject and determining the level of human soluble ST2 in the sample using at least one antibody or antibody fragment described herein. An elevated or substantially the same level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 indicates that the individual has an increased risk of dying within one year (e.g., an increased risk of dying within one year). year compared to subjects (e.g. subjects having or diagnosed with the same disease) who have a decreased level of human soluble ST2 in the sample compared to the same reference level of human soluble ST2). A decreased level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 indicates that the individual has a decreased risk of death within one year (e.g., a decreased risk of death within one year compared to individuals ( (e.g., individuals having or diagnosed with the same disease) who have an elevated or substantially the same level of human soluble ST2 in the sample compared to the same reference level of human soluble ST2). The level of risk of death within a year determined by the methods described here will depend on the disease state.
[00099] In some embodiments, the individual who has not been diagnosed or is not exhibiting one or more (eg, two, three, four, or five) symptoms of a disease. In some embodiments, the individual has already been diagnosed as having a disease (eg, heart failure, coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure, stroke, or any of the diseases described herein). In some embodiments, the individual has one or more (eg, one, two, three, or four) of hypertriglyceridemia, hypercholesterolemia, hypertension, and a body mass index > 30. In some embodiments, the determination is performed using at least one (eg. example, two, three, four or five) antibodies or fragments described herein.
[000100] In some embodiments, the reference level of human soluble ST2 is a threshold level of human soluble ST2 (e.g., a mean level of human soluble ST2 or a percentile (e.g., 75th, 80th, 85th, 90th or 95th percentile or any of the ranges or concentrations listed in Table 9) of the mean level of human soluble ST2 in a healthy patient population, e.g. a healthy male patient population or a healthy male patient population women). In some embodiments, the reference level may be a level of human soluble ST2 present in a sample from a subject who does not have one or more symptoms of a disease associated with increased levels of ST2. In some embodiments, the reference level may be a level of human soluble ST2 present in a sample from a subject not diagnosed as having a disease (e.g., heart failure, coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure). , stroke, or any of the diseases described herein) or an individual identified as not being at risk of developing a disease (e.g., any of the diseases described herein). Additional reference levels can be determined by those skilled in the art.
[000101] In some embodiments, the reference level of human soluble ST2 is between about 30 ng/mL to about 35 ng/mL. In some embodiments, where the subject has heart failure, the reference level of human soluble ST2 is between about 30 ng/mL to about 35 ng/mL. In some embodiments, the reference level of human soluble ST2 is about 35 ng/mL or about 60 ng/mL.
[000102] In some embodiments, the sample contains blood, serum, or plasma. The sample can be obtained and determination of the level of human soluble ST2 using at least one antibody or fragment described herein can be performed as described herein. Methods of Determining Discharge or Initiation or Continued Treatment of an Individual on an In-Hospital Basis
[000103] Methods are also provided for determining the discharge or initiation or continuation of treatment of an individual on a hospital basis, including obtaining a sample from an individual and determining the level of human soluble ST2 in the sample using at least one (e.g., two) antibody or antibody fragment described herein, where an elevated level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 indicates that hospital treatment (e.g., hospitalization or admission to a health) of the subject should be started or continued and a decreased or equal level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 indicates that the subject can be discharged from the hospital. The method may be performed several times for the same individual to determine whether hospital treatment should be continued (e.g., performed once a week, twice a week, three times a week, once a month, twice a week). month, three times a month and four times a month).
[000104] In some embodiments, the individual has not been diagnosed, is not exhibiting two or more symptoms of a disease state, or has not been identified as being at risk of developing a disease (eg, any of the diseases described herein). In some embodiments, the individual has been diagnosed as having a disease (e.g., heart failure, coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure, stroke, or any of the conditions described herein), has one or more symptoms of a disease (e.g., any of the diseases described herein) or has been identified as being at risk of developing a disease (e.g., any of the diseases described herein). In some modalities, the individual has one or more (eg, one, two, three, or four) of hypertriglyceridemia, hypercholesterolemia, hypertension, and a body mass index > 30. In some modalities, the individual has not yet been diagnosed as having heart failure , coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure, stroke or any of the diseases described herein. In some embodiments, determination of the level of human soluble ST2 is performed using at least two antibodies or antibody fragments described herein.
[000105] In some embodiments, the human soluble ST2 reference levels can be any of the reference levels described herein. Additional human soluble ST2 reference levels can be determined by those skilled in the art. In some embodiments, the sample contains blood, serum, or plasma. The sample can be obtained and determination of the level of human soluble ST2 using at least one antibody or fragment described herein can be performed as described herein. Methods of Selecting an Individual to Participate in a Clinical Trial
[000106] Methods for selecting an individual to participate in a clinical trial are also provided. These methods include obtaining a sample from a subject, determining the level of human soluble ST2 in the sample using at least one antibody or antibody fragment described herein, and selecting the subject to participate in a clinical study if the human soluble ST2 level of the subject against a reference level of human soluble ST2 indicates that the subject should be selected for participation in a clinical trial. In some embodiments, the presence of an elevated level of human soluble ST2 indicates that the subject should be selected for participation in a clinical trial. In some embodiments, the presence of an elevated level of human soluble ST2 indicates that the subject should be excluded from participation in a clinical trial.
[000107] In some embodiments, the individual has not been diagnosed, is not exhibiting one or more symptoms of a disease (e.g., any of the diseases described herein), or has not been identified as being at risk of developing a disease (e.g., any of the diseases described here). In some modalities, the individual has been diagnosed as having a disease (e.g., heart failure, coronary artery disease; cardiovascular disease, acute coronary syndrome, renal failure, stroke, or any of the conditions described herein), has one or more symptoms of a disease (e.g., any of the diseases described herein) or has been identified as having a low risk of developing a disease (e.g., any of the diseases described herein). In some embodiments, the individual has one or more (eg, one, two, three, or four) of hypertriglyceridemia, hypercholesterolemia, hypertension, and a body mass index > 30. In some embodiments, determination of human soluble ST2 level is performed using at least two antibodies or antibody fragments described herein.
[000108] In some embodiments, the human soluble ST2 reference levels can be any of the reference levels described herein. Additional human soluble ST2 reference levels can be determined by those skilled in the art. In some embodiments, the sample contains blood, serum, or plasma. The sample can be obtained and determination of the level of human soluble ST2 using at least one antibody or fragment described herein can be performed as described above. Methods for Selecting a Treatment
[000109] Methods are also provided for selecting a therapeutic treatment for an individual, including obtaining a sample from the individual and determining the level of human soluble ST2 in the sample using at least one of the antibodies or fragments described herein, in which an elevated level of ST2 soluble human in the sample relative to a reference level of human soluble ST2 indicates that the subject should be provided with a specific therapeutic treatment. For example, specific treatment can be selected from the group of: nitrates, calcium channel blockers, diuretics, thrombolytic agents, digitalis, renin-angiotensin-aldosterone system (RAAS) modulating agents (e.g. alprenolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, sotalol, timolol, cebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol, and nebivolol), angiotensin converting enzyme inhibitors (eg, benazepril, captopril, enalapril) , fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril), aldosterone antagonists (e.g., spironolactone, eplerenone, canrenone (potassium canrenoate), prorenone (potassium prorenoate), and mexrenone (potassium mexrenoate)), renin (e.g., aliskiren, remikiren, and enalkiren), and angiotensin II receptor blockers (e.g., valsartan, telmisartan, losartan, irbesartan, and olmesartan)), and cholesterol-lowering agents (eg, a statin). Additional treatment methods are also known in the art for example Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume, 9th Edition. Specific treatment can also be the administration of at least one or more of the new therapeutic agents to the subject, a change (e.g., increase or decrease) in the frequency, dosage or extent of administration of the one or more therapeutic agents to the subject, or the removal of of one or more therapeutic agents of the subject's treatment regimen. Treatment may also be the individual's hospital care (eg, admission or readmission of the individual to a hospital (eg, intensive care unit or critically ill unit) or health care facility). In some modalities, the treatment is surgery (eg, organ or tissue transplantation or angioplasty).
[000110] In some embodiments, the human soluble ST2 reference levels can be any of the reference levels described herein. Additional human soluble ST2 reference levels can be determined by those skilled in the art. In some embodiments, the sample contains blood, serum, or plasma. The sample can be obtained and determination of the level of human soluble ST2 using at least one antibody or fragment described herein can be performed as described above. Methods for Diagnosing an Individual
[000111] The methods described here are useful in a wide variety of clinical settings. For example, such methods can be used for screening a general population, including screening by physicians, for example, in hospitals and outpatient clinics, as well as in the emergency room.
[000112] In some embodiments, the methods described herein are useful in determining the probability of the presence of a disease in an individual. Increased levels of human soluble ST2 are generally associated with the presence of certain diseases such as, without limitation, cardiovascular disease, lung disease, sepsis, Kawasaki disease or a Th2-associated disease or any of the diseases described herein.
[000113] A Th2-associated disease is a disease associated with an abnormal type 2 (Th2) T helper cell response. A Th2-associated disease is a disease characterized by several factors, including without limitation, the presence of THF-alpha, IL-4, -5, -6, -10, and -13, but not IFN-gamma (Robinson, J. Allergy Clin Immunol 92:313, 1993). CD4+ T cells are classified according to the cytokines they secrete. Th2 cells secrete large amounts of interleukin-4 (IL-4), IL-5 and IL-13, which promote antibody production by B cells and collagen synthesis by fibroblasts, whereas Th1 cells secrete large amounts of interferon-Y and associated pro-inflammatory cytokines. Th1-type and Th2-type cytokines can inter-regulate each other's responses. An imbalance of Th1/TH2 responses is thought to contribute to the pathogenesis of various infections, allergic responses, and autoimmune diseases. Certain exemplifying Th2-associated diseases include, without limitation, systemic lupus erythematosus and asthma, as well as inflammatory conditions that are primarily independent of a Th1 response, such as septic shock or trauma (Trajkovic et al., Cytokine Growth Factor Rev. 15:87-95, 2004; Brunner et al., Intensive Care Med. 30:1468-1473, 2004 ). Other exemplary Th2-associated diseases include pre-eclampsia and multiple sclerosis. In some embodiments, a Th2-associated disease is an autoimmune disease. An autoimmune disease typically results when the individual's immune system is activated against one or more components (cells, tissues, or free cell or tissue molecules) of the individual and attacks the individual's own normal organs, tissues, or cells. Exemplary autoimmune diseases include, but are not limited to, adrenergic drug resistance, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, allergic encephalomyelitis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inflammatory eye disease , autoimmune neonatal thrombocytopenia, autoimmune neutropenia, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune thyroiditis, Behcet's disease, bullous pemphigoid, cardiomyopathy, post-cardiotomy syndrome, celiac-dermatie sprue, chronic active hepatitis, chronic fatigue syndrome with immune dysfunction ( CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, scar pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, dense deposit disease, diseases associated with organ transplant effects, discoid lupus, essential mixed cryoglobulinemia , fibromyalgia-f fibromyositis, glomerulonephritis (eg, IgA nephropathy), gluten-sensitive enteropathy, Goodpasture syndrome, graft vs. (GVHD), Graves' disease (including, for example, Graves' thyroiditis and Graves' ophthalmopathy), Guillain-Barre, hyperthyroidism (ie, Hashimoto's thyroiditis), idiopathic pulmonary fibrosis, idiopathic Addison's disease, thrombocytopenic purpura idiopathic (ITP), IgA neuropathy, Insulin Resistance Syndrome, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, Metabolic Syndrome, mixed connective tissue disease, multiple sclerosis, Myasthenia Gravis, myocarditis, diabetes (eg, type I diabetes or type II diabetes), neuritis, other endocrine disorders, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, Polyendocrinopathies, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, post-myocardial infarction, primary agammaglobulinemia, cirrhosis primary biliary, psoriasis, psoriatic arthritis, Raynaud's phenomenon, relapsing polychondritis, Reiter's syndrome, rheumatic heart disease ca, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, Takayasu's arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, urticaria, uveitis, uveitis ophthalmia, vasculitis such as vasculitis of the dermatitis herpetiformis, vitiligo and Wegener's granulomatosis.
[000114] A cardiovascular disease is a disorder of the heart and blood vessels and includes disorders of the arteries, veins, arterioles, venules and capillaries. Cardiovascular diseases diagnosed by the method described herein may include, without limitation, congestive heart failure (HF), acute coronary artery disease (CAD), arrhythmia, asymmetric septal hypertrophy (e.g., left ventricular hypertrophy with resulting diastolic dysfunction), cardiomyopathy, valvular dysfunction, pericarditis, atherosclerosis and acute myocardial infarction (MI).
[000115] A lung disease is a disorder of the lungs. Lung diseases diagnosed by the methods described herein may include, without limitation, chronic obstructive pulmonary disease (COPD), asthma, pneumonia, pneumothorax, pulmonary embolism, advanced respiratory distress syndrome (ARDS), pleural effusion, metastatic disease, pulmonary edema, gastroesophageal reflux with aspiration, interstitial fibrosis, pneumoconiosis, granulomatous disease, collagen vascular disease and restrictive lung disease.
[000116] If the individual has an elevated level of human soluble ST2, for example, as compared to a baseline level, a decision may be made to treat the individual aggressively and the individual may be, for example, admitted to a hospital for treatment. inpatient treatment, for example, in a hospital (for example, an acute or critical intensive care department) or in a health care institution. Determining whether the subject has a disease such as cardiovascular disease, or lung disease, sepsis, Kawasaki disease or a Th2-associated disease or any of the diseases described herein is desirable in a variety of situations. For example, portable test kits could allow emergency medical personnel to assess an individual in the field to determine whether he or she should be transported to an emergency department. In addition, triage decisions, for example, in an emergency department or other clinical setting, may be made based on information provided by a method described herein. Those patients who exhibit increased levels of human soluble ST2 may be prioritized over those with lower levels.
[000117] In some embodiments, the human soluble ST2 level is determined once, for example, at the time the individual is suspected of having a disease (e.g., after presentation to a healthcare professional or a health care facility). health). In some embodiments, the human soluble ST2 level is determined at one or more of 2, 4, 6, 8, 12, 18, and/or 24 hours and/or 1 to 7 days or more after the time when it is suspected the individual has an illness (for example, after presentation to a healthcare professional or healthcare facility).
[000118] In some embodiments, the human soluble ST2 level is determined more than once. In some embodiments where the human soluble ST2 level is determined more than once, the highest level may be used or the change in levels may be determined and used. Human soluble ST2 levels can also be determined multiple times to assess the individual's response to a treatment. For example, the human soluble ST2 level assessed after the administration of a treatment, for example, one or more doses or treatment rounds, can be compared to the human soluble ST2 levels before the treatment was started, for example, a basal level. The change in human soluble ST2 levels may indicate whether the treatment was effective; for example, a reduction in human soluble ST2 levels may indicate that the treatment was effective.
[000119] In some embodiments, the human soluble ST2 level in an individual is assayed and compared to the reference human soluble ST2 level. Any of a variety of techniques known to those skilled in the art can be used to assay human soluble ST2 levels in an individual. Exemplary assay methods include, without limitation, methods known in the art such as quantitative PCR and Northern blot analysis. In some embodiments, the level of human soluble ST2 in a subject is assayed using immunoassays such as enzyme-linked immunosorbent assays (ELISA). For example, in some embodiments, an antibody or antigen-binding fragment thereof described herein is contacted with a sample from the subject. A sample may comprise or be derived from any of a variety of cells or tissues from an individual. For example, a sample may include one or more of blood, serum or plasma. Binding of the antibody or antibody fragment is then detected and optionally quantitated and protein levels determined based on the binding levels of the antibody or antibody fragment. In some embodiments the sample does not substantially contain the ST2L form of the ST2 protein, such that all or most of the ST2 in the sample detected according to the methods described herein is human soluble ST2. In some embodiments, a sample contains no detectable ST2L, such that the only detectable ST2 in the sample is soluble human ST2. In some embodiments, a sample that contains substantially no detectable ST2L or ST2L is a serum or blood sample. In some embodiments, levels of human soluble ST2 in a subject are assayed in immunoassays that use at least one antibody or antigen-binding fragment described herein. As described in more detail in the Examples section below, antibody compositions comprising antibodies produced by the hybridoma deposited with the ATCC and designated by Patent Application Designation PTA-10431 exhibit increased affinity for the human soluble ST2 antigen when compared to other commercially available antibodies. available. Such antibodies can be used in accordance with the methods described herein.
[000120] The methods described herein are useful in determining that an individual does not have a condition associated with ST2. A condition associated with ST2 is a condition that is associated with elevated levels of ST2. Certain exemplary ST2-associated conditions include, without limitation, cardiovascular disease, lung disease, sepsis, Kawasaki disease, and Th2-associated diseases. Conditions associated with ST2 are usually serious and aggressive treatment is often indicated. Individuals who exhibit certain non-specific symptoms may or may not have an ST2-associated condition (eg, cardiovascular disease, lung disease, sepsis, Kawasaki disease, and Th2-associated diseases. Non-specific symptoms include, but are not limited to, pain or discomfort chest pain, dyspnea, nausea, vomiting, belching, sweating, palpitations, delirium, fatigue, and syncope.Each symptom may have a different etiology.
[000121] In some embodiments, the methods described here are useful in risk stratification, for example, determining which individual has a less severe or low-risk form of an ST2-associated condition. For example, certain individuals who have cardiovascular disease (e.g., myocardial infarction or heart failure) have a low risk of adverse consequences, such as death or a recurrent cardiac event, and also exhibit a lower concentration of human soluble ST2 than is normal. observed with other individuals who have a cardiovascular disease with an increased risk of adverse consequences. Such individuals may be considered to have a "less severe" or "low risk" form of an ST2-related cardiovascular condition. In both low-risk and high-risk populations, however, higher concentrations of human soluble ST2 are observed than in individuals who do not have a condition associated with ST2. Individuals who have a less severe form of ST2-related condition typically have human soluble ST2 concentrations greater than the reference level of human soluble ST2 (e.g., the average human soluble ST2 concentration of healthy or normal individuals), whereas Individuals who have a more severe form of an ST2-related condition typically have human soluble ST2 concentrations greater than the 80th percentile of a reference level of human soluble ST2 (e.g., human soluble ST2 concentrations observed in normal individuals). or healthy). Determining that an individual exhibits certain non-specific symptoms does not have or has a less severe form of the ST2-associated condition may result in improved diagnosis and/or more effective treatment decisions, for example, such an individual may not require aggressive treatment. For example, patients with high concentrations of human soluble ST2 after acute myocardial infarction exhibited more cardiac remodeling (increased fibrosis) than patients with low concentrations of human soluble ST2 and differentially attenuated cardiac remodeling with eplerenone in subjects who exhibited high concentrations of ST2 human soluble (Weir et al., J. Am. Coll. Cardiol. 55:243-250, 2010). Therefore, human soluble ST2 concentrations can be used to identify patients who should receive a different, possibly non-standard, hospital or more aggressive treatment. Chest pain
[000122] Chest pain is the primary complaint in about 1 to 2 percent of outpatient visits, and although the cause is usually noncardiac, heart disease remains the leading cause of death in the United States. Therefore, distinguishing between serious and benign causes of chest pain is crucial. The methods described herein are useful in making that determination.
[000123] An individual presenting to an emergency department with chest pain may have esophageal pain, an ulcer, acute lung problems such as pulmonary embolism (PE) (potentially fatal), aneurysm rupture or dissection (highly lethal), colic gallbladder disease, pericarditis (inflammation of the sac around the heart), angina pectoris (heart pain without injury) or myocardial infarction (potentially fatal). An accurate diagnosis can be difficult to make immediately, but the decision to hospitalize or aggressively treat the individual must be made immediately. If the methods described herein indicate that the individual has an elevated level of human soluble ST2, for example, suffers from an ST2-associated condition, the decision may be made to treat the individual aggressively, for example, to prevent a potentially adverse consequence that could result from a treatment failure. Additional information on the treatment and diagnosis of chest pain can be found, for example, in Cayley (Am. Fam. Phys. 72(10):2012-2028, 2005). dyspnea
[000124] Dyspnea or shortness of breath (also defined as abnormal or uncomfortable breathing) is a common symptom of individuals presenting to an emergency department. The differential diagnosis of dyspnea includes four general categories: (1) cardiac, (2) pulmonary, (3) cardiac or mixed pulmonary, and (4) non-cardiac or non-pulmonary.
[000125] Cardiac causes of dyspnea include right, left, or biventricular congestive heart failure with resultant systolic dysfunction, coronary artery disease, recent or remote myocardial infarction, cardiomyopathy, valvular dysfunction, left ventricular hypertrophy with resultant diastolic dysfunction, asymmetric septal hypertrophy, pericarditis and arrhythmias.
[000126] Pulmonary causes include obstructive (eg, chronic obstructive pulmonary disease (COPD) and asthma) and restrictive (eg, extrapulmonary causes such as obesity, spine or chest wall deformities, and an intrinsic pulmonary pathology such as interstitial fibrosis, pneumoconiosis, granulomatous disease, or collagen vascular disease) Mixed cardiac and pulmonary disorders include COPD with pulmonary hypertension and cor pulmonale, lack of conditioning, pulmonary embolus, ARDS, and trauma. Non-cardiac and non-lung disorders include metabolic conditions such as anemia, diabetic ketoacidosis and other, less common causes of metabolic acidosis, pain in the chest wall or elsewhere in the body, and neuromuscular disorders such as multiple sclerosis and muscular dystrophy. Rhinolaryngeal obstructive problems include nasal obstruction due to polyps or deviated septum, enlarged tonsils, and restriction of the supraglottic or subglottic airways.
[000127] Dyspnea can also be a somatic manifestation of psychiatric disorders, for example, an anxiety disorder with resulting hyperventilation. Additional information regarding the assessment and treatment of dyspnea can be found, for example, in Morgan and Hodge, Am. Fam. Phys. 57(4):711-718, 1998.
[000128] Any of the antibodies or antigen-binding fragments described herein can be used in determining that the individual does not have an ST2-associated condition. In some embodiments, the level of human soluble ST2 in a subject is assayed (e.g., by any of the methods described above) and compared to a reference level of human soluble ST2. If the level of human soluble ST2 in an individual is similar to the reference level of human soluble ST2, it can be determined that the individual has a very small probability of having an ST2-associated condition. A human soluble ST2 level in an individual is "similar" to a reference level of human soluble ST2 when the two levels are sufficiently close in range that the individual is unlikely to have a condition associated with ST2. Generally, a human soluble ST2 level in an individual is "similar" to a reference level of human soluble ST2 when the two levels are within about 25% of each other, for example, within about 25%, 20 %, 15%, 10%, 5% or less. Those skilled in the art will be able to determine appropriate reference levels of human soluble ST2 for the ST2-associated condition in question. Those skilled in the art will be aware of normal variations in such levels of human soluble ST2 and upon reading the present disclosure will be able to determine whether a given level of human soluble ST2 is similar to a reference level of human soluble ST2.
[000129] In some embodiments, the human soluble ST2 level is determined once, for example, at the time the individual is suspected of having an ST2-associated condition. In some embodiments, the human soluble ST2 level is determined at one or more than 2, 4, 6, 8, 12, 18, and/or 24 hours and/or 1 to 7 days after the subject is suspected of having have a condition associated with ST2. In some embodiments, the human soluble ST2 level is determined more than once, for example, to confirm or check the human soluble ST2 level determined in the first assay.
[000130] In some embodiments, the antibodies that bind human soluble ST2 and antigen-binding fragments thereof described herein can be used in one or more methods described in US Patent Application Publication Nos. US 2007/0248981 , US 2009/0264779 , US 2009/0305265 , and US 2010/0009356 , and PCT Application Publication No. WO2007/131031 .
[000131] In some embodiments, methods of diagnosing a disease in an individual include obtaining a sample from an individual, determining the level of human soluble ST2 in the sample using at least one antibody or fragment described herein, and the level of at least one (eg. (e.g. two, three, four or five) additional marker, wherein an elevated level of human soluble ST2 in the sample compared to a reference level of human soluble ST2 and an altered (e.g., increased or decreased) level of at least one additional marker relative to a reference level of at least one (e.g., two, three, four, or five) additional marker, indicates that the individual has the disease (e.g., cardiovascular disease, a lung disease, sepsis, Kawasaki or a Th2-associated disease or any of the diseases described herein). A reference level of at least one additional marker may be the level of the marker in an individual not diagnosed as having the disease, the level of the marker in an individual who does not have two or more symptoms of the disease, an individual who is not at risk of developing the disease or level in the same individual at an early time point. Additional markers are known in the art and methods for determining reference levels of additional markers can be determined by those skilled in the art.
[000132] In some embodiments, human soluble ST2 reference levels can be any reference levels described herein. Additional reference levels of human soluble ST2 can be determined by those skilled in the art. In some embodiments, the sample contains blood, serum, or plasma. The sample can be obtained and determination of the level of human soluble ST2 using at least one antibody or fragment described herein can be performed as described above. Therapeutic Methods
[000133] In some embodiments, an antibody that binds to ST2 or an antigen-binding fragment thereof is administered to a subject to treat any of a variety of diseases or conditions (e.g., any of the diseases described herein) . For example, human soluble ST2 levels are elevated in individuals who have diseases such as, without limitation, cardiovascular disease, lung disease, sepsis, Kawasaki disease, and/or a Th2-associated disease. Any of the antibodies that bind human soluble ST2 or antigen-binding fragments thereof, as well as modified antibodies or antigen-binding fragments based on such antibodies or fragments (e.g., human, chimeric, or humanized antibodies or fragments thereof ), can be used to treat such diseases or conditions.
[000134] In some embodiments, a subject is treated with an antibody or antigen-binding fragment thereof that competitively binds with an antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) and designated by the PTA Patent Deposit Designation -10431 or PTA-10432 or both. In some embodiments, the subject is treated with an antibody or antigen-binding fragment thereof described herein that is human, chimeric, or humanized. As is known in the art, such human, chimeric or humanized antibodies and fragments thereof offer therapeutic benefits such as, without limitation, decreased incidence of side effects, increased dose tolerance, and improved pharmacokinetic and/or pharmacodynamic properties. In some embodiments, a human, chimeric or humanized antibody or fragments thereof to be administered to a subject, is derived from an antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10431 or PTA-10432 or both. For example, the heavy and/or light chain variable regions of such antibodies can be linked to a human constant region or a fragment thereof to create a chimeric antibody or fragment. Alternatively, one or more CDRs (e.g. each of the CDRs) of such antibodies can be inserted into one or more human framework regions to create a humanized antibody or fragment.
[000135] In some embodiments, an anti-human soluble ST2 antibody or an antibody fragment that binds human soluble ST2 is administered directly to a subject. A soluble human anti-ST2 antibody or fragment can be administered in an effective amount, at dosages, and for periods of time necessary to obtain the desired result. For example, a therapeutically effective amount of the antibody or fragment may vary according to factors such as the disease state, age, sex and weight of the subject, and the ability of the antibody or fragment to elicit a desired response in the subject. Dosage regimens can be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be reduced proportionately as indicated by the requirements of the therapeutic situation. Those skilled in the art will be aware of dosages and dosage regimens suitable for administering a soluble human anti-ST2 antibody or fragment to a subject. See, for example, Physicians' Desk Reference, 63rd edition, Thomson Reuters, November 30, 2008.
[000136] Soluble human anti-ST2 antibodies or human soluble anti-ST2 antibody fragments described herein may be formulated for release by any available route, including but not limited to parenteral (e.g., intravenous), intradermal, subcutaneous, oral, nasal, bronchial, ophthalmic, transdermal (topical), transmucosal, rectal and vaginal. Antibodies or fragments may include a releasing agent (e.g., a cationic polymer, peptide molecular carrier, surfactant, etc.) in combination with a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds may also be incorporated into pharmaceutical formulations that contain an antibody or antigen-binding fragment thereof as described herein. kits
[000137] Kits are also provided that include a reagent comprising at least one (e.g., at least two, three, four or five) soluble human anti-ST2 antibody or a fragment that binds the antigen described herein. Kits are generally comprised of the following main elements: packaging, reagents comprising binding compositions as described above, optionally a control and instructions. The package may be a box-like structure to contain a vial (or several vials) containing said binding compositions, a vial (or several vials) containing a control and instructions for use in a method described herein. Individuals skilled in the art can readily modify the packaging to suit individual needs.
[000138] In some embodiments, a kit provided herein may contain at least one (e.g., at least two, three, four, or five) of any of the soluble human anti-ST2 anti-ST2 antibodies or an antigen-binding fragment described herein. . For example, a kit may contain at least one (e.g., at least two, three, four, or five) soluble human anti-ST2 antibody or an antigen-binding fragment that competitively binds with an antibody produced by a deposited hybridoma. in the American Type Culture Collection (ATCC) and designated by Patent Filing Designation PTA-10431 or PTA-10432 or both.
[000139] In some embodiments, a kit provided herein may contain at least one (e.g., at least two, three, four, or five) soluble human anti-ST2 anti-ST2 antibodies or antigen-binding fragments described herein and one or more reagents to detect binding of the antibody or antigen-binding fragment to human soluble ST2. For example, the kit may be designed for use in a chemiluminescent microparticle assay (CMIA) such as the ARCHITECT assays from Abbott Diagnostics (Abbott Park, IL) and therefore may contain paramagnetic microparticles coated with anti-BNP antibodies and microparticles paramagnetic cells coated with human soluble anti-ST2 antibodies. These microparticles are contacted with a sample and the human soluble ST2 present in the sample can bind to the coated microparticles. Optionally, the particle can be divided into at least two aliquots and each microparticle type can be contacted with a separate aliquot. After washing, an acridinium-labeled soluble human anti-ST2 antibody conjugate can be added to create a second step reaction mixture. After another wash cycle, pre-stimulation and stimulation solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured, for example, using ARCHITECT i System optics (Abbot Diagnostics, Abbott Park, Illinois). There is a direct relationship between the amount of human soluble ST2 in the sample and the chemiluminescence detected.
[000140] In some embodiments, a kit provided herein may contain at least one (e.g., at least two, three, four or five) soluble human anti-ST2 anti-ST2 antibodies or antigen-binding fragments described herein and one or more components solid phase immunoassay to detect human soluble ST2 by solid phase analysis. Solid phase immunoassays employ a solid support to which a member of a ligand-receptor pair, for example, an antibody or antigen-binding fragment thereof, is attached. Non-limiting examples of solid supports include plates, tubes, polystyrene spheres and various porous materials such as, for example, nylon, nitrocellulose, cellulose acetate and glass fibers. See, for example, Pat. U.S. Nos. 4,703,017; 4,743,560; and 5,073,484. In some embodiments, a kit comprises components for a solid-phase immunoassay, in which an antibody or antigen-binding fragment is bound on the solid phase (e.g., human soluble anti-ST2 antibodies or antigen-binding fragments thereof) is contacted with a sample that contains an analyte of interest (eg, human soluble ST2) after which the solid phase is washed to remove unbound material.
[000141] In some embodiments, a kit contains components for a solid phase flow immunoassay. Solid-phase flow immunoassays avoid the need for the incubation and washing steps associated with other types of solid-phase immunoassays. A variety of solid phase flow immunoassays are known in the art. For example, US Patent No. 4,632,901 describes a solid-phase flow immunoassay device in which an antibody (specific for a target antigen analyte) is attached to a porous membrane or filter to which a sample liquid is added. As the liquid flows through the membrane, the target analyte binds to the antibody. The addition of the sample is followed by the addition of the labeled antibody. Visual detection of labeled antibody provides an indication of the presence of a target antigen analyte in the sample. In addition, Pat. U.S. No. 5,229,073 describes a semiquantitative competitive immunoassay by the lateral flow method that employs a plurality of capture zones or lines containing immobilized antibodies to measure plasma lipoprotein levels. Additional examples of lateral flow tests to detect analytes are described in U.S. Pat. U.S. No. 4,168,146; 4,366,241; 4,703,017; 4,855,240; 4,861,711; and 5,120,643; European Patent No. 0296724; WO 97/06439; and WO 98/36278. Those skilled in the art will be aware of other suitable solid phase immunoassay methods and devices and will be able to employ one or more human soluble anti-ST2 antibodies or antigen-binding fragments described herein in such methods and devices.
[000142] In some embodiments, other detection methods may be used, for example, colorimetric assays, radioimmunoassays, or chemiluminescent assays. Sandwich assays can be used as well, for example using two monoclonal antibodies, one labeled with iodine 125 and the other adsorbed onto beads, for example as used in the IRMA-BNP2 kit from CISBIO International (France) and the ShionoRIA BNP or ANP kits ( SHIONOGI USA Inc.).
[000143] Kits as provided herein may be used in accordance with any of the methods (eg diagnostic methods) described above. For example, kits that contain at least one (e.g., at least two, three, four, or five) anti-human soluble ST2 antibodies or antigen-binding fragments described herein can be used to determine the level of human soluble ST2. in a sample. In addition, kits that contain at least one (e.g., at least two, three, four, or five) anti-human soluble ST2 antibodies or antigen-binding fragments described herein can be used to determine the level of human soluble ST2. of reference. Those skilled in the art will be aware of other suitable uses for the kits provided herein and will be able to employ the kits for such uses.
[000144] In some embodiments of the kits, at least one (e.g., at least one, two, three, four) antibodies or fragments have a KD for binding to human soluble ST2 equal to or less than 8.59 x 10- 10 M. Some embodiments of the kits further contain a recombinant human soluble ST2 isolated from a human cell (e.g., a human embryonic kidney cell). Some kits embodiments still contain a fully glycosylated soluble human ST2 (eg, present in a cell extract or supplied as an isolated protein). EXAMPLES
[000145] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. Example 1: Production and Characterization of Anti-ST2 Monoclonal Antibodies
[000146] Monoclonal antibodies to human soluble ST2 protein (sST2) were produced by immunizing mice with the recombinant protein produced from the cDNA sequence for sST2.
[000147] Antigen Production and Confirmation: A human sST2 cDNA clone, GeneBank Accession Number NM_003856.2, was purchased from Origene Technologies, Inc. of Rockville, MD. Using standard PCR techniques, this clone was used as the sequence source to create an expression vector that includes the complete human soluble ST2 sequence with a hexahistidine purification tag incorporated into the amino-terminal region of the protein. The integrity of the expression clone was confirmed by DNA sequencing. The recombinant protein was produced by transient transfection and expression in human embryonic kidney cells (HEK293). Recombinant human soluble ST2 protein was purified by passing the cell lysate over a metal chelate column that specifically binds to the histidine purification tag incorporated into the expressed protein. Purification of recombinant human soluble ST2 was confirmed by Coomassie-stained polyacrylamide gel and Western blot analysis using commercially available anti-ST2 antibodies (monoclonal antibody D067 obtained from MBL International) as well as anti-His tag antibodies. See, FIGs 1, 2 and 3A-3C. The protein itself has a molecular weight of 36 kD, based on amino acid sequence and was shown by Kuroiwa et al. (Biochem. Biophys. Res. Comm. 284:1104-1108, 2001), that the native protein in human serum has a molecular weight of ~58 kD. The purified recombinant protein produced from this expression system had the appropriate molecular weight of ~58 kD of a fully glycosylated protein and was properly recognized by commercially available anti-ST2 antibodies. Quantitation was performed by the Bradford total protein assay.
[000148] Production of Hybridoma and Monoclonal Antibody: Monoclonal antibodies were produced by immunizing mice with the recombinant protein produced as described above. Three Balb/c mice were immunized as follows: T1 20 μg/animal with CFA (Complete Freund's Adjuvant) T1 + 3 days 20 μg/animal with IFA (Incomplete Freund's Adjuvant) T1 + 6 days 20 μg/animal in Salina T1 + 9 days 20 μg/animal in Salina
[000149] After the final immunization, the antibody titer was determined from a puncture in the tail of each animal. The animal with the highest antibody titer was used for splenic fusion and hybridoma establishment. After establishing the hybridomas as stable cell cultures in 96-well plates, they were screened for binding to recombinant human soluble ST2 protein and to a generic protein containing a hexa-his purification tag to eliminate hybridomas specific to that tag. Two hybridomas were selected for further characterization and product development: 7E4 and 9F8. Both monoclonal antibodies were tested for sensitivity to recombinant human soluble ST2 antigen by coating individual wells in 96-well microtiter plates with consistent amounts of each antibody, 7E4 and 9F8, then tested against serial three-fold dilutions of soluble ST2 biotin-conjugated recombinant human, concentration range from 300 to 0.41 ng/mL (see figure 4).
[000150] The two antibodies illustrate the comparable sensitivity of the analyte with a very steep absorbance value, ~1.0, observed at the lowest analyte concentration tested, 0.41 ng/mL. Additionally, both antibodies were coated onto individual wells of a 96-well plate at concentrations ranging from 5 µg/ml to 0 and tested against a single concentration of biotin-conjugated recombinant human soluble ST2 (see Figure 5). Both antibodies exhibited significant sensitivity at a concentration of >1.25 μg/ml with the 9F8 antibody illustrating a slightly higher sensitivity.
[000151] The 9F8 and 7E4 antibodies were also tested for their ability to be used together in a monoclonal antibody sandwich enzyme immunoassay (EIA) setup. Each monoclonal antibody was coated onto individual wells of a 96-well microtiter plate at a constant concentration and assayed against a range of three-fold serial dilutions of human soluble sST2 concentrations from 10 ng/ml to 0.01 ng/ml , using the other biotin-conjugated monoclonal antibody for the detection of the complex. As shown in Figure 6, both antibody combinations result in comparable sensitivity and readily detect as little as 0.01 ng/ml of soluble human ST2.
[000152] Additional analysis using surface plasma resonance (SPR) confirmed that the 9F8 and 7E4 antibodies each recognize unique epitopes and epitopes that are different from those recognized by commercially available antibodies D066 and D067, the monoclonal antibodies used by MBL International Corporation (MBL) in your ELISA. Figure 7 illustrates the results of an SPR analysis of antibodies 9F8, 7E4, a third new soluble human anti-ST2 antibody included by reference (11A7), both monoclonal antibodies commercially available from MBL (D066 and D067), plus an irrelevant antibody to the determination of the baseline. An individual SPR chip was prepared with a coating for each monoclonal antibody. Recombinant human soluble ST2 was flowed through the chip and allowed to bind. Then, the test monoclonal antibodies were flowed through the first antibody-human soluble ST2 complex to assess whether the second antibody could also bind to the complex through the human soluble ST2 protein. Only secondary antibodies that recognize an epitope other than the primary antibody will bind to the complex.
[000153] The results of the SPR analysis are shown in Figs. 7A-F.
[000154] Graph A1 (Figure 7A): When the 9F8 antibody was used as the primary capture antibody, each test antibody demonstrated at least a minimal measurable signal. Test antibody 7E4 (L2) had the highest signal, irrelevant antibody (L6) had the lowest signal. The conclusion of this graph is that the 9F8 antibody recognized a different epitope than any of the test antibodies and that the 9F8-7E4 pair provided the strongest overall binding.
[000155] Graph A2 (Figure 7B): When the 7E4 antibody (A2) was used as the primary capture antibody, the test antibody 9F8 (L1) showed very good binding, the irrelevant antibody showed no measurable signal and the antibodies remaining test samples showed a low but measurable signal. The conclusion from this graph is that the 7E4 antibody recognizes an epitope different from any of the test antibodies and that the 9F8-7E4 pair provided the strongest overall binding.
[000156] Graph A3 (Figure 7C): When antibody 11A7 (A3) was used as the primary capture antibody, test antibody 9F8 (L1) showed very good binding, irrelevant antibody showed no measurable signal and antibodies remaining test samples showed a low but measurable signal. These results were nearly identical to results generated using the 7E4 antibody as the capture antibody.
[000157] Graph A4 (Figure 7D): When MBL antibody D066 (A4) was used as the primary capture antibody, test antibody 9F8 (L1) showed very good binding, followed in binding strength by antibody 7E4 ( L2). The irrelevant antibody showed no measurable signal and the remaining test antibodies showed a low but measurable signal. The conclusion from this plot is that antibody D066 recognized an epitope different from any of the test antibodies and that it formed a binding pair with the second MBL antibody, D067, but with a much lower binding affinity than the pair. 9F8-7E4.
[000158] Graph A5 (Figure 7E): When MBL antibody D067 (A5) was used as the primary capture antibody, test antibody 9F8 (L1) showed very good binding, followed in binding strength by antibody 7E4 ( L2) and D066 (L4). The irrelevant antibody showed no measurable signal and the 11A7 antibody showed very low signal. The conclusion from this plot is that antibody D067 recognized an epitope different from that of any of the test antibodies and that it formed a binding pair with the second MBL antibody, D066, but with much lower binding affinity than the pair. 9F8-7E4.
[000159] Graph A6 (Figure 7F): When the irrelevant antibody was used as the primary capture antibody, there was no measurable signal generated from any of the test antibodies, confirming the specificity of the tested antibodies for soluble ST2 affinity human.
[000160] Analysis confirmed that the novel anti-human soluble ST2 monoclonal antibodies 9F8 and 7E4 recognized different epitopes from monoclonal antibodies D066 and D067. Furthermore, this analysis also confirmed that the 9F8-7E4 pair had a higher binding affinity than the D066-D067 pair.
[000161] This increased binding affinity observed for the 9F8-7E4 pair was confirmed in the direct comparison of the two monoclonal antibody pairs in human plasma test samples. In the experiment summarized in Table 1, MBL ELISA comprised of the D066-D067 antibody pair was compared to the new 9F8-7E4 antibody pair. Four (4) plasma samples were tested in a 2-fold serial dilution, a matched pair of EDTA plasma and heparin plasma from a donor with a low concentration of soluble human ST2 and both EDTA plasma and heparin plasma samples from a donor with a high concentration of human soluble ST2 were used. Table 1: Comparison of Sensitivity D066-D067 and 9F8-7E4 with Human Plasma Samples
LS = sample with low concentration of sST2, HS = sample with high concentration of sST2, ND = not detected, EUL = exceeds the upper limit of detection
[000162] The results in Table 1 were generated by using each assay optimized for its individual performance with results reported in ng/mL based on the calibrator optimized for each antibody pair. The mass amounts reported here do not match as the calibrator proteins were not normalized to each other but were quantified independently. As shown in Table 1, the limit of detection for the D066-D067 pair was the 1:4 dilution of the LS EDTA sample and with poor accuracy, while the 9F8-7E4 pair was capable of accurate measurement below a 1:256 dilution with good accuracy, CV <10%. This difference in sensitivity is consistent when the HS EDTA plasma sample was tested. Also of note, the D066-D067 pair was not able to detect the less dilute LS heparin plasma sample and with the HS samples the plasma heparin sample had a much lower signal than the EDTA plasma sample with the D066-D067 pair. , indicating the sensitivity or inhibition of this pair of antibodies by heparin. The 9F8-7E4 pair did not exhibit this sensitivity to heparin and maintained good accuracy, low CV, in both low and high human soluble ST2 test plasma samples. Example 2: EIA characterization for the 9F8-7E4 monoclonal antibody pair
[000163] The characteristics of the 9F8-7E4 monoclonal antibody pair were analyzed in an enzyme immunoassay (EIA).
[000164] Functional Sensitivity (Limit of Quantification): The functional sensitivity limit was determined by assaying various concentrations of calibrator diluted in replicates of 20. In addition to the buffered blank, the calibrator concentrations tested included 0.0625, 0.125 and 0.25 ng/ml. Functional sensitivity is defined as the lowest concentration that results in a CV < 20%. As shown in Table 2 below, all concentrations tested met this criterion with the lowest concentration tested being 0.0625 ng/mL. Table 2: Summary of Functional Sensitivity Analysis

[000165] SPR was also used to determine the affinity of four antibodies produced by the methods described herein (9F8, 7E4, 11A7 and 15D06) and two antibodies produced by MBL international (D066-3 and D067-3). Each experiment was performed by detecting the binding of the following concentrations of the recombinant human soluble ST2 protein used to prepare the 9F8 and 7E4 antibodies described herein: 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.25 nM and the nM Data from these experiments are shown in Figures 8A-8F. The calculated K D of each antibody for binding to recombinant human soluble ST2 isolated from human embryonic kidney cells is shown in Table 3. Table 3. The K D of binding of each antibody to human soluble ST2.

[000166] Precision: Assessment of assay precision was performed according to the Clinical and Laboratory Standards Institute (CLSI) guideline Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline-Second Edition. (InVitro Diagnostics) EP5-A2. Pooled plasma samples from three patients were aliquoted into twenty 1.5 mL plastic tubes for each concentration level and frozen at -80°C. These samples were analyzed in duplicate on one run per day for 20 days after 2 months of blood collection. In-run and total analytical (CVA) imprecision was calculated with the CSLI single-run assessment test. The assay had an in-run CVA of 2.4% and a total CVA of 4.0% at an average concentration of 11 ng/mL (pool 1, low), an in-run CVA of 2.0%, and a Total CVA of 3.9% at an average concentration of 87 ng/mL (pool 2, average) and an in-run CVA of 2.2% and a total CVA of 3.9% at an average concentration of 140 ng/mL mL (pool 3, high). See Table 4. Table 4: Summary of Precision Analysis

[000167] The assay does not exhibit any deviation in accuracy across the tested concentration range.
[000168] Assessment of Interfering Substances (Anticoagulant Sensitivity): In thirty apparently healthy volunteers, plasma samples were collected in the most common tube types: serum, EDTA plasma, citrate plasma and heparin plasma. The analysis was performed immediately after normal centrifugation and processing of the samples in a single human soluble ST2 analysis kit. Volunteers consisted of 9 men and 21 women aged 22 to 66 years. The results of this analysis are summarized in Table 5. As seen in Table 5, the mean value for the citrate tube was slightly lower than for other tube types, which is not unexpected as the citrate tubes had a small volume. of anticoagulant liquid in the tube which introduces a modest dilution of the collected sample in relation to other types of tube that do not influence the volume of the sample. To test the consistency of measurements, each type of plasma tube was compared with the serum tube. Each comparison resulted in a highly significant R2 value, ranging from 0.849 to 0.964. Therefore, with the exception of the modest dilution in the citrate tubes that may influence the measurements of normal concentration, there was no measurement deviation by tube type. Table 5: Summary of Anticoagulant Test Results

[000169] Determination of the Reference Range of Normal Concentration: A cohort comprised of 490 donors, self-described as healthy with no known serious illness or currently being treated for any serious illness, equally distributed between the sexes and with age representation between 18 to 84 years , were recruited for this analysis.
[000170] Table 6 provides a summary of the number of subjects in each age group and by sex for this healthy baseline cohort and Figure 10 is a histogram of the distribution of human soluble ST2 concentration. In Figure 10, the bars represent actual data and the vertical lines within the bars represent a theoretical normal distribution. The distribution of concentrations in these healthy subjects was not normal. Table 7 compares human soluble ST2 concentrations as a function of sex. In this normal healthy population, the mean concentration in men was significantly higher than in women (Kruskal-Wallis test; p < 0.0001). Table 6: Healthy Reference Range Cohort
Table 7: Comparison of reference groups by mean values by sex

[000171] Stratification of human soluble ST2 concentrations by age revealed that there were no significant differences between these groups, figure 11 (Kruskal-Wallis test; men p=0.501, women p=0.056). Therefore, sex-specific baseline values as well as values for the entire group were calculated using a nonparametric (90% one-sided) percentile method. These results are summarized in Table 8. Table 8: Summary of the Healthy CCD Reference Group

[000172] Table 9 lists the concentration of human soluble ST2 at various specific thresholds. Table 9: sST2 Concentrations at Specific Thresholds of the Healthy Self-Reported US Cohort

[000173] Fasted versus Staying Non-Fasting Human Soluble ST2 Concentrations: A plasma sample was collected from twenty-five patients (19 men and 6 women) with various disease states (8 of them with type 2 diabetes mellitus ) after an overnight fasting period at 7:00 h. After that, the patients ate a standardized breakfast (730 kcal per patient without diabetes and 522 kcal for those with diabetes). A second blood draw for the determination of human soluble ST2 was at 11:00 h. Afterwards, all patients had a standardized lunch (800 kcal per patient without diabetes and 716 kcal for those with diabetes). The third and last blood collection was at 14:00 h. Mean human soluble ST2 concentrations from the 25 subjects were calculated for all three time points. Paired t-tests were used to determine whether there was a difference between plasma concentrations of human soluble ST2 without fasting (i.e., collections at 11:00 h and 14:00 h) compared to the respective fasting values (i.e., blood collection at 7:00 am). The relative change of human soluble ST2 concentrations over time was compared with RCV to assess the effect of food on analyte concentration.
[000174] The mean fasting human soluble ST2 concentration was 18 U/mL (median, 17 U/mL; range 9-26 U/mL) at 7:00 h, the mean human soluble ST2 concentration after coffee in the morning was 19 U/mL (median, 18 U/mL; range 11-28 U/mL; p=0.025 for comparison of fasting ST2) at 11:00 h and the mean human soluble ST2 concentration after lunch was of 18 U/mL (median, 19 U/mL; range 1-28 U/mL; p=0.014 for comparison of fasting human soluble ST2) at 14:00 h. Mean human soluble ST2 concentrations at 11:00 h and 14:00 h were then <5% greater than the fasting value obtained at 7:00 h.
[000175] Comparison of Normal Soluble Human Soluble ST2 Concentrations and Disease State Concentrations: Human soluble ST2 concentrations were distinctly higher in heart failure patients than in normal, healthy subjects. In the following analysis, the normal concentration as determined in 490 healthy donors was compared with several distinct populations: 528 healthy volunteers confirmed by biomarker screening to be free of occult cardiovascular disease (CVD) or inflammatory disease (screened by BNP, PCT, CRP and IL-6), 709 patients diagnosed with acute heart failure, 1159 patients diagnosed with stable, chronic heart failure, 190 patients diagnosed with pulmonary arterial hypertension (PAH), 48 patients diagnosed with asthma, 223 diagnosed with asthma or COPD, 58 diagnosed with pulmonary embolism (PE), 119 diagnosed with pneumonia (PNA), 109 diagnosed with advanced respiratory disease syndrome (ARDS), 50 young people diagnosed with Kawasaki disease (KD), and 15 diagnosed with sepsis. Table 10 lists the mean values, 95% confidence interval, and interquartile range (IQR) for human soluble ST2 concentrations in each group. Table 10: sST2 Concentrations by Disease State


[000176] Comparison of Human Soluble ST2 Concentrations and 1 Year Risk of Death: Human soluble ST2 concentrations were also measured in blood samples from the PRIDE cohort (Junuzzi et al., J. Am. Coll. Cardiol. 50: 607-613, 2007). Of the 599 subjects in the original PRIDE cohort, 586 had blood samples available for the assessment of human soluble ST2 using the methods described above. The samples used were aliquots of EDTA plasma frozen at -80°C. Receiving charts of operator characteristics (ROC) with death in one year as reference standard were analyzed and the areas under the curve (AUC) were compared according to the method of Hanley et al. (Radiology 148:839-843, 1983), to determine the assay's ability to predict 1-year all-cause mortality in the PRIDE cohort.
[000177] In these experiments, the mean concentrations for the entire cohort were 27 ng/mL (mean, < 1-393 ng/mL) for the assay. In this cohort, a nonparametric correlation analysis revealed a correlation coefficient (rs ) of 0.955 (95%CI, 0.947-0.962; p < 0.001) for both methods. Of the 586 patients, 92 (16%) subjects died within one year and 494 (84%) survived. ROC curve analyzes demonstrated an AUC of 0.803 (95% CI, 0.768-0.834) by the assay for predicting death at 1 year. OTHER MODALITIES
[000178] It should be understood that, although the invention has been described in conjunction with its detailed description, the preceding description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

权利要求:
Claims (17)
[0001]
1. Isolated antibody or fragment that binds to its antigen, characterized in that it specifically binds to the soluble human growth stimulation 2 (ST2) gene, in which the antibody or fragment is produced by the hybridoma deposited in the American Type Culture Collection (ATCC) and designated by Patent Filing Designation PTA-10432.
[0002]
2. Antibody or fragment according to claim 1, characterized in that the antibody or fragment has a KD for binding to human soluble ST2 equal to or less than 8.59 x 10-10 M as determined using surface plasmon resonance .
[0003]
3. Antibody or fragment, according to claim 1, characterized in that the antibody or fragment is chimeric or humanized.
[0004]
4. Antibody or fragment, according to any one of claims 1 to 3, characterized in that the fragment is selected from the group consisting of: a Fab fragment, an F(ab')2 fragment and an scFv fragment.
[0005]
5. Antibody or fragment, according to any one of claims 1 to 4, characterized in that the antibody or fragment is glycosylated.
[0006]
6. Antibody or fragment, according to any one of claims 1 to 5, characterized in that the antibody is the antibody produced by the hybridoma deposited with the ATCC and designated by Patent Deposit Designation PTA-10432.
[0007]
7. Hybridoma, characterized in that it is deposited with the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10432.
[0008]
8. Kit, characterized in that it comprises: (i) an antibody or fragment as defined in claims 1 to 6; and (ii) an antibody produced by a hybridoma deposited with the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10431 or antigen-binding fragment thereof
[0009]
9. Method for quantifying a level of human soluble ST2 in a sample from an individual, the method characterized in that it comprises: contacting the sample with at least one antibody or fragment, as defined in claims 1 to 6; and detecting binding of the antibody or fragment to human soluble ST2.
[0010]
10. In vitro method for predicting the risk of death within one year in an individual, the method characterized in that it comprises: determining the level of the soluble human growth stimulation 2 (ST2) expressed gene level in a sample comprising blood , serum or plasma from an individual using an isolated antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10432, or an antigen-binding fragment of an antibody produced by the hybridoma deposited in the ATCC and designated by Patent Application Designation PTA-10432; and identifying an individual with an elevated level of human soluble ST2 in the sample compared to a threshold level of human soluble ST2 as having an increased risk of death within one year, or identifying an individual with a decreased or equal level of human soluble ST2 in the sample compared to the reference level of human soluble ST2 as having a decreased risk of death within one year.
[0011]
11. Method according to claim 10, characterized in that the antigen-binding fragment of the antibody produced by the hybridoma deposited with the ATCC and designated by Patent Application Designation PTA-10432 has a KD for binding to human soluble ST2 equal to or less than 8.59 x 10-10 M as determined using surface plasmon resonance.
[0012]
12. Method according to claim 10 or 11, characterized in that the level of soluble human growth stimulation 2 (ST2) expressed gene level in the sample is determined using (i) an isolated antibody produced by the hybridoma deposited at American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10432, or an antigen-binding fragment of an antibody produced by the hybridoma deposited with the ATCC and designated by Patent Deposit Designation PTA-10432; and (ii) an isolated antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) and designated by Patent Application Designation PTA-10431, or an antigen-binding fragment of an antibody produced by the hybridoma deposited with the ATCC and designated by the Patent Application Designation PTA-10431.
[0013]
13. Method according to claim 12, characterized in that the antigen-binding fragment of the antibody produced by the hybridoma deposited with the ATCC and designated by Patent Application Designation PTA-10431 has a KD for binding to human soluble ST2 equal to or less than 1.51 x 10 -9 M as determined using surface plasmon resonance.
[0014]
14. Method according to claim 10 or 12, characterized in that the step of determining the level of human soluble ST2 in the sample comprises the use of isolated antibody or isolated antibodies, respectively.
[0015]
15. Method according to claim 10 or 12, characterized in that the individual is male and the human soluble ST2 reference level is 37.4 ng/mL.
[0016]
16. Method according to claim 10 or 12, characterized in that the individual is female and the human soluble ST2 reference level is 23.7 ng/mL.
[0017]
17. Method according to claim 10 or 12, characterized in that the individual has hypertriglyceridemia, hypercholesterolemia, hypertension, renal failure, or body mass index > 30.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6563976B2|2019-08-21|Soluble human ST-2 antibody and assay

---

Finckh et al.2010|Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

---

AU2019200747B2|2020-09-17|Soluble human ST-2 antibodies and assays

---

AU2013204182B2|2016-09-15|Soluble human ST-2 antibodies and assays

---

EP3482208A1|2019-05-15|Adrenomedullin for assessing congestion in a subject with acute heart failure

同族专利:

---

公开号 | 公开日

---

IL262649A|2021-12-01|

---

RU2012147638A|2014-05-27|

---

DK2556090T3|2016-05-30|

---

JP2015091798A|2015-05-14|

---

RU2625014C2|2017-07-11|

---

ES2571994T3|2016-05-27|

---

RS54762B1|2016-10-31|

---

US9150654B2|2015-10-06|

---

EP2556090A2|2013-02-13|

---

MX360543B|2018-10-24|

---

EP3050901A1|2016-08-03|

---

SG10201704453YA|2017-07-28|

---

US20130177931A1|2013-07-11|

---

SI2556090T1|2016-07-29|

---

WO2011127412A3|2012-01-26|

---

CN103154027B|2016-06-29|

---

RU2017121298A3|2019-01-28|

---

JP5635180B2|2014-12-03|

---

ES2859577T3|2021-10-04|

---

HRP20160461T1|2016-06-17|

---

JP2013523840A|2013-06-17|

---

IL262649D0|2018-12-31|

---

JP6849751B2|2021-03-31|

---

IL222276A|2018-11-29|

---

US20110256635A1|2011-10-20|

---

EP3434694B1|2020-12-30|

---

US8420785B2|2013-04-16|

---

RU2017121298A|2019-01-28|

---

RU2684724C2|2019-04-11|

---

US20200339695A1|2020-10-29|

---

JP2021092587A|2021-06-17|

---

US20150361177A1|2015-12-17|

---

IL222276D0|2012-12-31|

---

BR112012025728A2|2020-09-01|

---

WO2011127412A2|2011-10-13|

---

CN103154027A|2013-06-12|

---

AU2011237359B2|2016-02-04|

---

JP6151676B2|2017-06-21|

---

JP2019191199A|2019-10-31|

---

RU2019109844A|2020-10-05|

---

CN106620692B|2021-04-09|

---

JP6563976B2|2019-08-21|

---

AU2011237359A1|2012-11-01|

---

US10745484B2|2020-08-18|

---

PL2556090T3|2017-07-31|

---

EP3050901B1|2018-08-29|

---

CA2795200A1|2011-10-13|

---

CN106620692A|2017-05-10|

---

EP3434694A1|2019-01-30|

---

HUE027760T2|2016-11-28|

---

MX2012011667A|2013-03-05|

---

JP2017173337A|2017-09-28|

---

SG184450A1|2012-11-29|

---

EP2556090B1|2016-02-24|

---

ES2699591T3|2019-02-11|

---

CA2795200C|2020-01-14|

---

EP2556090A4|2013-08-21|

---

EP3848394A1|2021-07-14|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

SE388694B|1975-01-27|1976-10-11|Kabi Ab|WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES|

---

US4366241B1|1980-08-07|1988-10-18|

---

US5073484A|1982-03-09|1991-12-17|Bio-Metric Systems, Inc.|Quantitative analysis apparatus and method|

---

GB8308235D0|1983-03-25|1983-05-05|Celltech Ltd|Polypeptides|

---

US4816567A|1983-04-08|1989-03-28|Genentech, Inc.|Recombinant immunoglobin preparations|

---

US4703017C1|1984-02-14|2001-12-04|Becton Dickinson Co|Solid phase assay with visual readout|

---

US4743560A|1984-03-26|1988-05-10|Becton Dickinson And Company|Solid phase assay|

---

US4632901A|1984-05-11|1986-12-30|Hybritech Incorporated|Method and apparatus for immunoassays|

---

JPH0251559B2|1984-11-16|1990-11-07|Teijin Ltd|

---

DE3445816C1|1984-12-15|1986-06-12|Behringwerke Ag, 3550 Marburg|Flat diagnostic agent|

---

US5225539A|1986-03-27|1993-07-06|Medical Research Council|Recombinant altered antibodies and methods of making altered antibodies|

---

US4855240A|1987-05-13|1989-08-08|Becton Dickinson And Company|Solid phase assay employing capillary flow|

---

CA1313616C|1987-06-01|1993-02-16|Robert B. Sargeant|Lateral flow, non-bibulous membrane protocols|

---

US5120643A|1987-07-13|1992-06-09|Abbott Laboratories|Process for immunochromatography with colloidal particles|

---

US4975369A|1988-04-21|1990-12-04|Eli Lilly And Company|Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen|

---

US5530101A|1988-12-28|1996-06-25|Protein Design Labs, Inc.|Humanized immunoglobulins|

---

IL162181A|1988-12-28|2006-04-10|Pdl Biopharma Inc|A method of producing humanized immunoglubulin, and polynucleotides encoding the same|

---

DE69233254T2|1991-06-14|2004-09-16|Genentech, Inc., South San Francisco|Humanized Heregulin antibody|

---

US5229073A|1992-02-27|1993-07-20|Abbott Laboratories|One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein|

---

EP0831714A1|1995-06-07|1998-04-01|Merck & Co., Inc.|Monospecific antibodies and methods using them|

---

WO1997006439A1|1995-08-09|1997-02-20|Quidel Corporation|Test strip and method for one step lateral flow assay|

---

WO1998036278A1|1997-02-15|1998-08-20|Beth Israel Deaconess Medical Center, Inc.|Multiple-site antibody capture immunoassays and kits|

---

DE19711932A1|1997-03-21|1998-09-24|Anne Katrin Dr Werenskiold|An in vitro method for predicting the course of disease of patients with breast cancer and / or for diagnosing a breast carcinoma|

---

GB9727172D0|1997-12-24|1998-02-25|Univ Glasgow|Reagents specific for st2l and uses therefor|

---

GB9812545D0|1998-06-10|1998-08-05|Celltech Therapeutics Ltd|Biological products|

---

US6323334B1|1999-09-24|2001-11-27|Millennium Pharmaceuticals, Inc.|Nucleic acid molecules encoding a 103 gene product and uses therefor|

---

AU1887101A|2000-03-21|2001-10-03|Medical & Biol Lab Co Ltd|Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same|

---

US7432060B2|2000-11-09|2008-10-07|The Brigham And Women's Hospital, Inc.|Methods for diagnosis of cardiovascular disease|

---

US6872541B2|2001-07-25|2005-03-29|Coulter International Corp.|Method and compositions for analysis of pentraxin receptors as indicators of disease|

---

CN1668763B|2002-05-09|2012-05-16|布赖汉姆妇女医院|1L1RL-1 as a cardiovascular disease marker and therapeutic target|

---

WO2004081047A1|2003-03-14|2004-09-23|Taisho Pharmaceutical Co., Ltd.|Monoclonal antibody and hybridoma producing the same|

---

TW200732350A|2005-10-21|2007-09-01|Amgen Inc|Methods for generating monovalent IgG|

---

AU2006317242A1|2005-11-28|2007-05-31|Genmab A/S|Recombinant monovalent antibodies and methods for production thereof|

---

WO2007127749A2|2006-04-24|2007-11-08|Critical Care Diagnostics, Inc.|Predicting mortality and detecting severe disease|

---

AT517341T|2006-04-27|2011-08-15|Critical Care Diagnostics Inc|INTERLEUKIN-33 FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES|

---

PT2021796E|2006-05-01|2012-04-19|Critical Care Diagnostics Inc|Diagnosis of cardiovascular disease|

---

PT2019965E|2006-05-02|2015-08-28|Critical Care Diagnostics Inc|Differential diagnosis between pulmonary and cardiovascular disease|

---

WO2007140205A2|2006-05-24|2007-12-06|Biogen Idec Ma Inc.|Methods of treating fibrosis|

---

US8242247B2|2007-12-21|2012-08-14|Hoffmann-La Roche Inc.|Bivalent, bispecific antibodies|

---

PT2660599E|2008-04-18|2014-11-28|Critical Care Diagnostics Inc|Predicting risk of major adverse cardiac events|

---

EP2112149A1|2008-04-22|2009-10-28|Bayer CropScience Aktiengesellschaft|2-[-sulfonyl]-oxazole derivatives, 2-[-sulfanyl]-oxazole derivatives and chiral 2-[-sulfinyl]-oxazole derivatives, method for production of same and their use as herbicides and plant growth regulators|

---

CA2773585C|2009-09-09|2015-10-27|Herman Miller, Inc.|Partition system|

---

RU2684724C2|2010-04-09|2019-04-11|Критикал Кэа Дайэгностикс, Инк.|Soluble human st-2 antibodies and assays|

---

US8728742B2|2011-03-17|2014-05-20|Critical Care Diagnostics, Inc.|Methods predicting risk of an adverse clinical outcome|

---

BR112014001283A2|2011-07-18|2017-02-21|Critical Care Diagnostics Inc|Cardiovascular disease treatment methods and prevention of the effectiveness of exercise therapy|

---

AU2013262515B2|2012-05-18|2018-03-15|Cardiac Pacemakers, Inc.|Methods for treating or predicting risk of a ventricular tachyarrhythmia event|

---

DK2885641T3|2012-08-16|2018-01-29|Critical Care Diagnostics Inc|PROCEDURES FOR PREDICTING THE RISK OF HYPERTENSION DEVELOPMENT|

---

JP6450679B2|2012-08-21|2019-01-09|クリティカル ケア ダイアグノスティクス インコーポレイテッド|Multi-marker risk stratification|

---

CN106461636A|2014-01-10|2017-02-22|重症监护诊断股份有限公司|Methods and systems for determining risk of heart failure|US7432060B2|2000-11-09|2008-10-07|The Brigham And Women's Hospital, Inc.|Methods for diagnosis of cardiovascular disease|

---

CN1668763B|2002-05-09|2012-05-16|布赖汉姆妇女医院|1L1RL-1 as a cardiovascular disease marker and therapeutic target|

---

WO2007127749A2|2006-04-24|2007-11-08|Critical Care Diagnostics, Inc.|Predicting mortality and detecting severe disease|

---

AT517341T|2006-04-27|2011-08-15|Critical Care Diagnostics Inc|INTERLEUKIN-33FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES|

---

PT2021796E|2006-05-01|2012-04-19|Critical Care Diagnostics Inc|Diagnosis of cardiovascular disease|

---

PT2019965E|2006-05-02|2015-08-28|Critical Care Diagnostics Inc|Differential diagnosis between pulmonary and cardiovascular disease|

---

PT2660599E|2008-04-18|2014-11-28|Critical Care Diagnostics Inc|Predicting risk of major adverse cardiac events|

---

RU2684724C2|2010-04-09|2019-04-11|Критикал Кэа Дайэгностикс, Инк.|Soluble human st-2 antibodies and assays|

---

GB201013151D0|2010-08-04|2010-09-22|Isis Innovation|Diagnostic method|

---

US8728742B2|2011-03-17|2014-05-20|Critical Care Diagnostics, Inc.|Methods predicting risk of an adverse clinical outcome|

---

BR112014001283A2|2011-07-18|2017-02-21|Critical Care Diagnostics Inc|Cardiovascular disease treatment methods and prevention of the effectiveness of exercise therapy|

---

US20130157290A1|2011-12-16|2013-06-20|Yves Levy|Soluble st2 as a marker for disease|

---

US9090694B2|2012-04-30|2015-07-28|Janssen Biotech, Inc.|ST2L antibody antagonists|

---

JO3623B1|2012-05-18|2020-08-27|Amgen Inc|St2 antigen binding proteins|

---

AU2013262515B2|2012-05-18|2018-03-15|Cardiac Pacemakers, Inc.|Methods for treating or predicting risk of a ventricular tachyarrhythmia event|

---

CN105785028A|2012-08-10|2016-07-20|杭州华得森生物技术有限公司|Rapid diagnosis kit for detecting novel human cardiac failure marker ST2|

---

CN102830234A|2012-08-10|2012-12-19|杭州华得森生物技术有限公司|Rapid diagnostic kit for detecting novel marker ST2 of human heart failure|

---

DK2885641T3|2012-08-16|2018-01-29|Critical Care Diagnostics Inc|PROCEDURES FOR PREDICTING THE RISK OF HYPERTENSION DEVELOPMENT|

---

JP6450679B2|2012-08-21|2019-01-09|クリティカル ケア ダイアグノスティクス インコーポレイテッド|Multi-marker risk stratification|

---

CN106461636A|2014-01-10|2017-02-22|重症监护诊断股份有限公司|Methods and systems for determining risk of heart failure|

---

CN103926406A|2014-04-29|2014-07-16|安徽省立医院|Marker for indicating hepatitis infection and application of marker|

---

US10324089B2|2014-12-11|2019-06-18|Critical Care Diagnostics, Inc.|Test apparatus and methods for ST2 cardiac biomarker|

---

WO2016094761A2|2014-12-11|2016-06-16|Critical Care Diagnostics, Inc.|Test apparatus and methods for st2 cardiac biomarker|

---

US10079073B2|2014-12-11|2018-09-18|Critical Care Diagnostics, Inc.|Test apparatus and methods for ST2 cardiac biomarker|

---

CN105259353B|2015-10-15|2017-03-22|北京市心肺血管疾病研究所|Kit and method for detecting sST2in blood of abdominal aortic aneurysm and/or aortic dissection patient|

---

CN107765014B|2016-08-23|2019-11-19|上海费玛生物科技有限公司|A kind of method and kit detecting people sST2 albumen|

---

CN108956996A|2017-05-23|2018-12-07|深圳市安群生物工程有限公司|Detect the fluorescence immune chromatography test paper and preparation method thereof of people ST2 albumen|

---

CN107340386A|2017-06-09|2017-11-10|厦门大学附属中山医院|SST2 detection kits based on microparticle chemiluminescence immunoassay|

---

CN108152486A|2017-12-22|2018-06-12|太原瑞盛生物科技有限公司|The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of human soluble ST2|

---

KR20210084587A|2018-10-31|2021-07-07|데리니아, 인크.|Multivalent Regulatory T Cell Modulators|

---

CN110208549A|2019-07-01|2019-09-06|北京利德曼生化股份有限公司|A kind of Soluble growth stimulation 2 albumen sST2 luminescence reagent box of expressing gene|

---

CN110357963B|2019-07-31|2020-09-18|北京智仁美博生物科技有限公司|Anti-human ST2 antibodies and uses thereof|

---

CN111308086B|2020-02-21|2022-02-25|苏州旭光科星抗体生物科技有限公司|Enzyme-linked immunoassay kit for detecting soluble ST2 content and application thereof|

---

CN111863259A|2020-08-06|2020-10-30|复旦大学附属中山医院|Prognosis model for evaluating tumor immunotherapy-associated myocarditis based on sST2 and application thereof|

---

CN112457392B|2021-01-27|2021-04-27|天津奇云诺德生物医学有限公司|Soluble ST2 protein antigenic determinant polypeptide and application thereof|

---

CN113912729B|2021-12-08|2022-03-04|南京融捷康生物科技有限公司|Single-domain antibody aiming at sST2, and derivative protein and application thereof|

法律状态:
2020-09-15| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-11-17| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-05-04| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-05-25| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-11-09| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2022-01-11| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US32257810P| true| 2010-04-09|2010-04-09|

---

US61/322,578|2010-04-09|

---

US34583710P| true| 2010-05-18|2010-05-18|

---

US61/345,837|2010-05-18|

---

PCT/US2011/031801|WO2011127412A2|2010-04-09|2011-04-08|Soluble human st-2 antibodies and assays|

---